Advertisements
Feeds:
Posts
Comments

Archive for the ‘Medical Devices R&D and Inventions’ Category


Rhythm Management Device Hardware (Dual-chamber Pacemaker) coupled with BackBeat’s Cardiac Neuromodulation Therapy (CNT) bioelectronic therapy for Lowering Systolic Blood Pressure for patients with Pacemakers

Reporter: Aviva Lev-Ari, PhD, RN

 

BackBeat’s CNT is a bioelectronic therapy that immediately, substantially and chronically lowers blood pressure (BP) while simultaneously modulating the autonomic nervous system (ANS).  Mimicking the effects of multiple medications by reducing pre-load, after-load and sympathetic tone, it can be delivered using standard rhythm management device hardware such as dual-chamber pacemakers.

For more information: www.orchestrabiomed.com

October 2, 2018 — Two-year results of the Moderato I Study demonstrated immediate, substantial and sustained reduction in blood pressure when BackBeat cardiac neuromodulation therapy (CNT) was used in patients with persistent hypertension (office BP > 150mmHg). Patients in the study had persistent hypertension despite two or more anti-hypertensive medications and an indication for a pacemaker.

Results of the multicenter clinical trial were presented at the 2018 Transcatheter Cardiovascular Therapeutics (TCT) conference, Sept. 21-25 in San Diego, by Daniel Burkhoff, M.D., Ph.D., director, heart failure, hemodynamics and mechanical circulatory support research for the Cardiovascular Research Foundation (CRF).

“The clinical efficacy and safety data observed with BackBeat CNT in a patient population with a significant portion of isolated systolic disease is very promising. Hypertension affects over 70 percent of pacemaker patients. These patients could benefit substantially from a potent hypertension therapy such as BackBeat CNT that could be included in their already necessary pacemaker,” said Prof. Petr Neuzil, M.D., head of the Department of Cardiology of Na Homolce Hospital in Prague, Czech Republic and one of the principal investigators of the study.

The 27 patients that met the study inclusion criteria were implanted with BackBeat’s proprietary Moderato dual-chamber pacemaker that incorporates the BackBeat CNT algorithms. The primary safety and efficacy endpoint results of the study were as follows:

  • Efficacy Outcomes: Immediate, substantial and sustained reduction in blood pressure.
    • 14.2 mmHg decrease from baseline (p<0.001) in 24 hours ambulatory systolic blood pressure (AMB BP) at 3 months
    • 23.4 mmHg decrease from baseline (p < 0.001) in systolic blood pressure (SBP) sustained out to 2 years
  • High responder rate in a population where 78 percent of patients had isolated systolic hypertension.
    • 85 percent AMB BP reduced >5mmHg
    • 74 percent AMB BP reduced >10 mmHg
  • Safety Outcomes: The study met the safety endpoint.
    • Observed reduction in end systolic and diastolic volumes with no change to ejection fraction suggests improvement of cardiac function
    • Observed reduction in heart rate out to 2 years indicative of reduced sympathetic activity

“These statistically significant results demonstrate the potential for BackBeat CNT to be a broadly applicable therapy that substantially lowers blood pressure immediately and maintains reduced pressures for years,” commented Burkhoff. “It is rare to see a new therapy show such dramatic and sustained effects in such a small number of patients.”

To further investigate the efficacy and safety of BackBeat CNT for the treatment of hypertension, Orchestra BioMed is enrolling patients into a prospective, 1:1 randomized double-blind active treatment (BackBeat CNT) versus standard medical therapy trial, Moderato II. The study will enroll patients with uncontrolled blood pressure (office systolic > 140, day and AMB BP > 130 mmHg) treated with at least one anti-hypertension medication that are indicated for a dual-chamber pacemaker. The primary efficacy endpoint of the first cohort of the study is the comparison of the mean reduction in 24-hour systolic ambulatory blood pressure following 6 months of therapy between the treatment and the control. Primary safety endpoint is the rate of major adverse cardiac event (MACE) at 6 months between the treatment and control.  The company is expecting results on the first cohort of patients in 2019.

SOURCE

https://www.dicardiology.com/content/backbeat-cardiac-neuromodulation-therapy-reduces-blood-pressure-two-years?eid=333021707&bid=2258792

Advertisements

Read Full Post »


Extraordinary Breakthrough in Artificial Eyes and Artificial Muscle Technology

Reporter: Irina Robu, PhD

Metalens, flat surface that use nanostructures to focus light promise to transform optics by replacing the bulky, curved lenses presently used in optical devices with a simple, flat surface.

Scientists at the Harvard John A. Paulson School of Engineering and Applied Sciences designed metalens who are mainly focused on light and minimizes spherical aberrations through a dense pattern of nanostructures, since the information density in each lens will be high due to nanostructures being small.

According to Federico Capasso, “This demonstrates the feasibility of embedded optical zoom and auto focus for a wide range of applications, including cell phone cameras, eyeglasses, and virtual and augmented reality hardware. It also shows the possibility of future optical microscopes, which operate fully electronically and can correct many aberrations simultaneously.”

However, when scientists tried to scale up the lens, the file size of the design alone would balloon up to gigabytes or even terabytes. And as a result, create a new algorithm in order to shrivel the file size to make the metalens flawless with the innovation currently used to create integrated circuits. Afterward, scientists follow the large metalens to an artificial muscle without conceding its ability to focus light. In the human eye, the lens is enclosed by ciliary muscle, which stretches or compresses the lens, changing its shape to adjust its focal length. Scientists at that moment choose a thin, transparent dielectric elastomer with low to attach to the lens.

Within the experiment, when the voltage is applied to elastomers, it stretches, the position of nanopillars on the surface of the lens shift. The scientists as a result show that the lens can focus instantaneous, control abnormalities triggered by astigmatisms, and achieve image shift. Since the adaptive metalens is flat, you can correct those deviations and assimilate diverse optical capabilities onto a single plane of control.

SOURCE

https://news.harvard.edu/gazette/story/2018/02/researchers-combine-artificial-eye-and-artificial-muscle

Read Full Post »


Top 100 of 415 articles published on PubMed in 2018 on TAVR

Reporter: Aviva Lev-Ari, PhD, RN

 

SOURCE

https://www.ncbi.nlm.nih.gov/pubmed  [2018 TAVR]

Select item 301029701.

Ninety-Day Readmissions of Bundled Valve Patients: Implications for Healthcare Policy.

Koeckert MS, Grossi EA, Vining PF, Abdallah R, Williams MR, Kalkut G, Loulmet DF, Zias EA, Querijero M, Galloway AC.

Semin Thorac Cardiovasc Surg2018 Aug 10. pii: S1043-0679(18)30168-0. doi: 10.1053/j.semtcvs.2018.07.017. [Epub ahead of print]

PMID:
30102970
Select item 300946422.

TAVR Vs. SAVR in Intermediate-Risk Patients: What Influences Our Choice of Therapy.

Still S, Szerlip M, Mack M.

Curr Cardiol Rep2018 Aug 9;20(10):82. doi: 10.1007/s11886-018-1026-3. Review.

PMID:
30094642
Select item 300945323.

Transcatheter aortic valve replacement in patients with severe aortic stenosis and heart failure.

Bavishi C, Kolte D, Gordon PC, Abbott JD.

Heart Fail Rev2018 Aug 9. doi: 10.1007/s10741-018-9726-8. [Epub ahead of print] Review.

PMID:
30094532
Select item 300930574.

Disarming the Ticking Time Bomb: Post-Procedure Electrocardiography Predictors of High-Degree Conduction Disturbances After Transcatheter Aortic Valve Replacement.

Nazif TM, Chen S, Kodali SK.

JACC Cardiovasc Interv2018 Aug 13;11(15):1527-1530. doi: 10.1016/j.jcin.2018.07.003. No abstract available.

PMID:
30093057
Select item 300930565.

Predictors of Advanced Conduction Disturbances Requiring a Late (≥48 H) Permanent Pacemaker Following Transcatheter Aortic Valve Replacement.

Mangieri A, Lanzillo G, Bertoldi L, Jabbour RJ, Regazzoli D, Ancona MB, Tanaka A, Mitomo S, Garducci S, Montalto C, Pagnesi M, Giannini F, Giglio M, Montorfano M, Chieffo A, Rodès-Cabau J, Monaco F, Paglino G, Della Bella P, Colombo A, Latib A.

JACC Cardiovasc Interv2018 Aug 13;11(15):1519-1526. doi: 10.1016/j.jcin.2018.06.014.

PMID:
30093056
Select item 300930556.

Immediate Post-Procedural 12-Lead Electrocardiography as Predictor of Late Conduction Defects After Transcatheter Aortic Valve Replacement.

Jørgensen TH, De Backer O, Gerds TA, Bieliauskas G, Svendsen JH, Søndergaard L.

JACC Cardiovasc Interv2018 Aug 13;11(15):1509-1518. doi: 10.1016/j.jcin.2018.04.011.

PMID:
30093055
Select item 300925577.

Von Willebrand factor and the aortic valve: Concepts that are important in the transcatheter aortic valve replacement era.

Ibrahim H, Rondina MT, Kleiman NS.

Thromb Res2018 Jul 30;170:20-27. doi: 10.1016/j.thromres.2018.07.028. [Epub ahead of print] Review.

PMID:
30092557
Select item 300893298.

Antiplatelet Treatment for Catheter-Based Interventions in High-Risk Patients: Current Guidelines and Expert Opinion.

Rath D, Gawaz M.

Hamostaseologie2018 Aug 8. doi: 10.1055/s-0038-1668165. [Epub ahead of print]

PMID:
30089329
Select item 300870259.

The Evolution of Echocardiographic Type and Anesthetic Technique for Transcatheter Aortic Valve Replacement at a High-Volume Transcatheter Aortic Valve Replacement Center.

Marino M, Lilie CJ, Culp WC Jr, Schepel SR, Tippett JC.

J Cardiothorac Vasc Anesth2018 Jun 30. pii: S1053-0770(18)30468-3. doi: 10.1053/j.jvca.2018.06.022. [Epub ahead of print]

PMID:
30087025
Select item 3007961110.

Propensity matched comparison of in-hospital outcomes of TAVR vs. SAVR in patients with previous history of CABG: Insights from the Nationwide inpatient sample.

Nalluri N, Atti V, Patel NJ, Kumar V, Arora S, Nalluri S, Nelluri BK, Maniatis GA, Kandov R, Kliger C.

Catheter Cardiovasc Interv2018 Aug 5. doi: 10.1002/ccd.27708. [Epub ahead of print]

PMID:
30079611
Select item 3007956111.

Permanent pacemaker implantation after transcatheter aortic valve replacement in bicuspid aortic valve patients.

Xiong TY, Liao YB, Li YJ, Zhao ZG, Wei X, Tsauo JY, Xu YN, Feng Y, Chen M.

J Interv Cardiol2018 Aug 5. doi: 10.1111/joic.12546. [Epub ahead of print]

PMID:
30079561
Select item 3007952212.

Effect of transcatheter aortic valve replacement on left atrial function.

Truong VT, Chung E, Nagueh S, Kereiakes D, Schaaf J, Volz B, Ngo TNM, Mazur W.

Echocardiography2018 Aug 5. doi: 10.1111/echo.14109. [Epub ahead of print]

PMID:
30079522
Select item 3007679413.

TAVR 2.0: Collaborating to Measure, Assure, and Advance Quality.

Shahian DM, Gleason TG, Shemin RJ, Carroll JD, Mack MJ.

Ann Thorac Surg2018 Aug 1. pii: S0003-4975(18)31034-8. doi: 10.1016/j.athoracsur.2018.07.004. [Epub ahead of print] No abstract available.

PMID:
30076794
Select item 3007608114.

Low Iodine Contrast Injection for CT Acquisition Prior to Transcatheter Aortic Valve Replacement: Aorta Assessment and Screening for Coronary Artery Disease.

Hachulla AL, Noble S, Ronot M, Guglielmi G, de Perrot T, Montet X, Vallée JP.

Acad Radiol2018 Aug 1. pii: S1076-6332(18)30330-1. doi: 10.1016/j.acra.2018.06.016. [Epub ahead of print]

PMID:
30076081
Select item 3007532615.

Variation in post-TAVR antiplatelet therapy utilization and associated outcomes: Insights from the STS/ACC TVT Registry.

Sherwood MW, Vemulapalli S, Harrison JK, Dai D, Vora AN, Mack MJ, Holmes DR, Rumsfeld JS, Cohen DJ, Thourani VH, Kirtane A, Peterson ED.

Am Heart J2018 Jul 9;204:9-16. doi: 10.1016/j.ahj.2018.06.006. [Epub ahead of print]

PMID:
30075326
Select item 3006878516.

State of Transcatheter Aortic Valve Implantation in Spain Versus Europe and Non-European Countries.

Biagioni C, Tirado-Conte G, Rodés-Cabau J, Ryan N, Cerrato E, Nazif TM, Eltchaninoff H, Sondergaard L, Ribeiro HB, Barbanti M, Nietlispach F, De Jaegere P, Agostoni P, Trillo R, Jiménez-Quevedo P, D’Ascenzo F, Wendler O, Maluenda G, Chen M, Tamburino C, Macaya C, Leon MB, Nombela-Franco L.

J Invasive Cardiol2018 Aug;30(8):301-309.

Select item 3006493717.

Accuracy of predicted orthogonal projection angles for valve deployment during transcatheter aortic valve replacement.

Steinvil A, Weissman G, Ertel AW, Weigold G, Rogers T, Koifman E, Buchanan KD, Shults C, Torguson R, Okubagzi PG, Satler LF, Ben-Dor I, Waksman R.

J Cardiovasc Comput Tomogr2018 May 26. pii: S1934-5925(18)30130-8. doi: 10.1016/j.jcct.2018.05.017. [Epub ahead of print]

PMID:
30064937
Select item 3006277818.

Absence of Electrocardiographic Left Ventricular Hypertrophy is Associated with Increased Mortality After Transcatheter Aortic Valve Replacement.

Kampaktsis PN, Ullal AV, Swaminathan RV, Minutello RM, Kim L, Bergman GS, Feldman DN, Singh H, Chiu Wong S, Okin PM.

Clin Cardiol2018 Jul 30. doi: 10.1002/clc.23034. [Epub ahead of print]

Select item 3005825919.

Early and midterm outcomes of transcatheter aortic valve replacement in patients with bicuspid aortic valves.

Aalaei-Andabili SH, Beaver TM, Petersen JW, Anderson RD, Karimi A, Thoburn E, Kabir A, Bavry AA, Arnaoutakis GJ.

J Card Surg2018 Jul 29. doi: 10.1111/jocs.13775. [Epub ahead of print]

PMID:
30058259
Select item 3005725220.

The Incidence of Dysphagia Among Patients Undergoing TAVR With Either General Anesthesia or Moderate Sedation.

Mukdad L, Kashani R, Mantha A, Sareh S, Mendelsohn A, Benharash P.

J Cardiothorac Vasc Anesth2018 May 26. pii: S1053-0770(18)30373-2. doi: 10.1053/j.jvca.2018.05.040. [Epub ahead of print]

PMID:
30057252
Select item 3005685121.

Sex-Specific Differences in Outcome of Transcatheter or Surgical Aortic Valve Replacement.

Kaier K, von Zur Mühlen C, Zirlik A, Schmoor C, Roth K, Bothe W, Hehn P, Reinöhl J, Zehender M, Bode C, Stachon P.

Can J Cardiol2018 Aug;34(8):992-998. doi: 10.1016/j.cjca.2018.04.009. Epub 2018Apr 12.

PMID:
30056851
Select item 3005602322.

Hemodynamic monitoring by pulse contour analysis during trans-catheter aortic valve replacement: A fast and easy method to optimize procedure results.

Ristalli F, Romano SM, Stolcova M, Meucci F, Squillantini G, Valente S, Di Mario C.

Cardiovasc Revasc Med2018 Jul 19. pii: S1553-8389(18)30314-2. doi: 10.1016/j.carrev.2018.07.015. [Epub ahead of print]

PMID:
30056023
Select item 3005418823.

TAVR Versus SAVR in the Era of NSQIP.

Vadlamudi R, Duggan M.

J Cardiothorac Vasc Anesth2018 May 26. pii: S1053-0770(18)30370-7. doi: 10.1053/j.jvca.2018.05.037. [Epub ahead of print] No abstract available.

PMID:
30054188
Select item 3005090924.

Expanding TAVI to Low and Intermediate Risk Patients.

Voigtländer L, Seiffert M.

Front Cardiovasc Med2018 Jul 12;5:92. doi: 10.3389/fcvm.2018.00092. eCollection 2018. Review.

Select item 3004863225.

Albumin Is Predictive of 1-Year Mortality After Transcatheter Aortic Valve Replacement.

Hebeler KR, Baumgarten H, Squiers JJ, Wooley J, Pollock BD, Mahoney C, Filardo G, Lima B, DiMaio JM.

Ann Thorac Surg2018 Jul 23. pii: S0003-4975(18)31022-1. doi: 10.1016/j.athoracsur.2018.06.024. [Epub ahead of print]

PMID:
30048632
Select item 3004178326.

Bioprosthetic structural valve deterioration: How do TAVR and SAVR prostheses compare?

Aldalati O, Kaura A, Khan H, Dworakowski R, Byrne J, Eskandari M, Deshpande R, Monaghan M, Wendler O, MacCarthy P.

Int J Cardiol2018 Oct 1;268:170-175. doi: 10.1016/j.ijcard.2018.04.091.

PMID:
30041783
Select item 3003771727.

Exposure to glucocorticoids prior to transcatheter aortic valve replacement is associated with reduced incidence of high-degree AV block and pacemaker.

Oestreich B, Gurevich S, Adabag S, Kelly R, Helmer G, Raveendran G, Yannopoulos D, Biring T, Garcia S.

Cardiovasc Revasc Med2018 Jul 18. pii: S1553-8389(18)30311-7. doi: 10.1016/j.carrev.2018.07.012. [Epub ahead of print]

PMID:
30037717
Select item 3003742428.

Comparison of Hospital Outcomes of Transcatheter Aortic Valve Implantation With Versus Without Hypothyroidism.

Subahi A, Yassin AS, Adegbala O, Akintoye E, Abubakar H, Elmoghrabi A, Ibrahim W, Ajam M, Pahuja M, Weinberger JJ, Levine D, Afonso L.

Am J Cardiol2018 Jun 5. pii: S0002-9149(18)31197-4. doi: 10.1016/j.amjcard.2018.05.025. [Epub ahead of print]

PMID:
30037424
Select item 3003171929.

Arrhythmic Burden as Determined by Ambulatory Continuous Cardiac Monitoring in Patients With New-Onset Persistent Left Bundle Branch Block Following Transcatheter Aortic Valve Replacement: The MARE Study.

Rodés-Cabau J, Urena M, Nombela-Franco L, Amat-Santos I, Kleiman N, Munoz-Garcia A, Atienza F, Serra V, Deyell MW, Veiga-Fernandez G, Masson JB, Canadas-Godoy V, Himbert D, Castrodeza J, Elizaga J, Francisco Pascual J, Webb JG, de la Torre JM, Asmarats L, Pelletier-Beaumont E, Philippon F.

JACC Cardiovasc Interv2018 Aug 13;11(15):1495-1505. doi: 10.1016/j.jcin.2018.04.016. Epub 2018 Jul 18.

PMID:
30031719
Select item 3003171830.

Arrhythmias and Conduction Disturbances Following Transcatheter Aortic Valve Replacement: Out of Sight, Out of Mind?

Pighi M, Piazza N.

JACC Cardiovasc Interv2018 Aug 13;11(15):1506-1508. doi: 10.1016/j.jcin.2018.05.038. Epub 2018 Jul 18. No abstract available.

PMID:
30031718
Select item 3002924731.

Numerical Parametric Study of Paravalvular Leak Following a Transcatheter Aortic Valve Deployment Into a Patient-Specific Aortic Root.

Mao W, Wang Q, Kodali S, Sun W.

J Biomech Eng2018 Oct 1;140(10). doi: 10.1115/1.4040457.

PMID:
30029247
Select item 3002920732.

Comparative Fluid-Structure Interaction Analysis of Polymeric Transcatheter and Surgical Aortic Valves’ Hemodynamics and Structural Mechanics.

Ghosh R, Marom G, Rotman O, Slepian MJ, Prabhakar S, Horner M, Bluestein D.

J Biomech Eng2018 Jun 25. doi: 10.1115/1.4040600. [Epub ahead of print]

PMID:
30029207
Select item 3002830433.

Extended benefits of TAVR in young patients with low-intermediate risk score: proceed with care.

Doshi R.

EuroIntervention2018 Jul 20;14(4):e485. doi: 10.4244/EIJ-D-18-00236L. No abstract available.

Select item 3002830034.

Valve-in-valve TAVR using the SAPIEN 3 transcatheter heart valve: still plagued by patient-prosthesis mismatch.

Saxon JT, Cohen DJ, Feldman T.

EuroIntervention2018 Jul 20;14(4):e377-e379. doi: 10.4244/EIJV14I4A66. No abstract available.

Select item 3002573135.

The SAVI-TF Registry: 1-Year Outcomes of the European Post-Market Registry Using the ACURATE neo Transcatheter Heart Valve Under Real-World Conditions in 1,000 Patients.

Kim WK, Hengstenberg C, Hilker M, Kerber S, Schäfer U, Rudolph T, Linke A, Franz N, Kuntze T, Nef H, Kappert U, Zembala MO, Toggweiler S, Walther T, Möllmann H.

JACC Cardiovasc Interv2018 Jul 23;11(14):1368-1374. doi: 10.1016/j.jcin.2018.03.023.

Select item 3002557236.

Transcatheter Aortic Valve Replacement of Failed Surgically Implanted Bioprostheses: The STS/ACC Registry.

Tuzcu EM, Kapadia SR, Vemulapalli S, Carroll JD, Holmes DR Jr, Mack MJ, Thourani VH, Grover FL, Brennan JM, Suri RM, Dai D, Svensson LG.

J Am Coll Cardiol2018 Jul 24;72(4):370-382. doi: 10.1016/j.jacc.2018.04.074.

PMID:
30025572
Select item 3002410237.

Transcatheter valve-in-valve versus redo surgical aortic valve replacement for the treatment of degenerated bioprosthetic aortic valve: A systematic review and meta-analysis.

Tam DY, Vo TX, Wijeysundera HC, Dvir D, Friedrich JO, Fremes SE.

Catheter Cardiovasc Interv2018 Jul 19. doi: 10.1002/ccd.27686. [Epub ahead of print]

PMID:
30024102
Select item 3001983938.

Predicted magnitude of alternate access in the contemporary transcatheter aortic valve replacement era.

Rogers T, Gai J, Torguson R, Okubagzi PG, Shults C, Ben-Dor I, Satler LF, Waksman R.

Catheter Cardiovasc Interv2018 Jul 18. doi: 10.1002/ccd.27668. [Epub ahead of print]

PMID:
30019839
Select item 3001982839.

Slope of left ventricular filling as an index of valvular and paravalvular regurgitation in native and prosthetic aortic valves.

Makki N, Ghao X, Whitson B, Shreenivas S, Crestanello J, Lilly S.

Catheter Cardiovasc Interv2018 Jul 18. doi: 10.1002/ccd.27684. [Epub ahead of print]

PMID:
30019828
Select item 3001982240.

Is two better than one? Re-evaluating the surgical approval process for TAVR.

Shreenivas S, Lilly S, Reardon M, Answini GA, Kereiakes DJ.

Catheter Cardiovasc Interv2018 Jul 18. doi: 10.1002/ccd.27666. [Epub ahead of print] No abstract available.

PMID:
30019822
Select item 3001816741.

Improving the Diagnostic Performance of 18F-FDG PET/CT in Prosthetic Heart Valve Endocarditis.

Swart LE, Gomes A, Scholtens AM, Sinha B, Tanis W, Lam MGEH, van der Vlugt MJ, Streukens SAF, Aarntzen EHJG, Bucerius J, van Assen S, Bleeker-Rovers CP, van Geel PP, Krestin GP, van Melle JP, Roos-Hesselink JW, Slart RHJA, Glaudemans AWJM, Budde RPJ.

Circulation2018 Jul 17. pii: CIRCULATIONAHA.118.035032. doi: 10.1161/CIRCULATIONAHA.118.035032. [Epub ahead of print]

PMID:
30018167
Select item 3001752042.

Software-automated multidetector computed tomography-based prosthesis-sizing in transcatheter aortic valve replacement: Inter-vendor comparison and relation to patient outcome.

Baeßler B, Mauri V, Bunck AC, Pinto Dos Santos D, Friedrichs K, Maintz D, Rudolph T.

Int J Cardiol2018 Jul 9. pii: S0167-5273(18)32256-3. doi: 10.1016/j.ijcard.2018.07.008. [Epub ahead of print] No abstract available.

PMID:
30017520
Select item 3001751843.

Inflammation in aortic stenosis: Shaping the biomarkers network.

Schiattarella GG, Perrino C.

Int J Cardiol2018 Jul 6. pii: S0167-5273(18)33669-6. doi: 10.1016/j.ijcard.2018.07.026. [Epub ahead of print] No abstract available.

PMID:
30017518
Select item 3001728244.

Inter- and intra-observer repeatability of aortic annulus measurements on screening CT for transcatheter aortic valve replacement (TAVR): Implications for appropriate device sizing.

Knobloch G, Sweetman S, Bartels C, Raval A, Gimelli G, Jacobson K, Lozonschi L, Kohmoto T, Osaki S, François C, Nagle S.

Eur J Radiol2018 Aug;105:209-215. doi: 10.1016/j.ejrad.2018.06.003. Epub 2018 Jun 15.

PMID:
30017282
Select item 3001614745.

Atherosclerosis on CT Angiogram Predicts Acute Kidney Injury After Transcatheter Aortic Valve Replacement.

Kandathil A, Abbara S, Hanna M, Minhajuddin A, Wehrmann L, Merchant AM, Mills R, Fox AA.

AJR Am J Roentgenol2018 Jul 17:1-7. doi: 10.2214/AJR.17.19340. [Epub ahead of print]

PMID:
30016147
Select item 3001289046.

Transfemoral Implantation of the Acurate neo for the Treatment of Aortic Regurgitation.

Toggweiler S, Cerillo AG, Kim WK, Biaggi P, Lloyd C, Hilker M, Almagor Y, Cuculi F, Brinkert M, Kobza R, Muller O, Rück A, Corti R.

J Invasive Cardiol2018 Jul 15. pii: JIC2018715-3. [Epub ahead of print]

Select item 3000980047.

Suprasternal and Left Axillary Transcatheter Aortic Valve Replacement in Morbidly Obese Patients.

Olds A, Eudailey K, Nazif T, Vahl T, Khalique O, Lewis C, Hahn R, Leon M, Bapat V, Ahmed M, Kodali S, George I.

Ann Thorac Surg2018 Jul 13. pii: S0003-4975(18)30978-0. doi: 10.1016/j.athoracsur.2018.05.095. [Epub ahead of print]

PMID:
30009800
Select item 3000336648.

Transcatheter valve-in-valve implantation (VinV-TAVR) for failed surgical aortic bioprosthetic valves.

Wernly B, Zappe AK, Unbehaun A, Sinning JM, Jung C, Kim WK, Fichtlscherer S, Lichtenauer M, Hoppe UC, Alushi B, Beckhoff F, Wewetzer C, Franz M, Kretzschmar D, Navarese E, Landmesser U, Falk V, Lauten A.

Clin Res Cardiol2018 Jul 12. doi: 10.1007/s00392-018-1326-z. [Epub ahead of print]

PMID:
30003366
Select item 3000209949.

Myocardial Scar and Mortality in Severe Aortic Stenosis: Data from the BSCMR Valve Consortium.

Musa TA, Treibel TA, Vassiliou VS, Captur G, Singh A, Chin C, Dobson LE, Pica S, Loudon M, Malley T, Rigolli M, Foley JRJ, Bijsterveld P, Law GR, Dweck MR, Myerson SG, McCann GP, Prasad SK, Moon JC, Greenwood JP.

Circulation2018 Jul 12. pii: CIRCULATIONAHA.117.032839. doi: 10.1161/CIRCULATIONAHA.117.032839. [Epub ahead of print]

PMID:
30002099
Select item 2999613850.

Aortic Angulation and TAVR.

Gandotra P.

Cardiology2018 Jul 11;140(3):141-142. doi: 10.1159/000490094. [Epub ahead of print] No abstract available.

Select item 2998906851.

Endovascular repair of severe aortic coarctation, transcatheter aortic valve replacement for severe aortic stenosis, and percutaneous coronary intervention in an elderly patient with long term follow-up.

Fallatah R, Elasfar A, Amoudi O, Ajaz M, AlHarbi I, Abuelatta R.

J Saudi Heart Assoc2018 Jul;30(3):271-275. doi: 10.1016/j.jsha.2018.01.003. Epub 2018 Feb 9.

Select item 2998711952.

Impact of Rapid Ventricular Pacing on Outcome After Transcatheter Aortic Valve Replacement.

Fefer P, Bogdan A, Grossman Y, Berkovitch A, Brodov Y, Kuperstein R, Segev A, Guetta V, Barbash IM.

J Am Heart Assoc2018 Jul 9;7(14). pii: e009038. doi: 10.1161/JAHA.118.009038.

Select item 2998314253.

Imaging Evaluation for the Detection of Leaflet Thrombosis After Transcatheter Aortic Valve Replacement.

Zhao ZG, Wang MY, Jilaihawi H.

Interv Cardiol Clin2018 Jul;7(3):293-299. doi: 10.1016/j.iccl.2018.03.007. Epub 2018Jun 29. Review.

PMID:
29983142
Select item 2998314154.

Imaging Evaluation and Interpretation for Vascular Access for Transcatheter Aortic Valve Replacement.

Foley TR, Stinis CT.

Interv Cardiol Clin2018 Jul;7(3):285-291. doi: 10.1016/j.iccl.2018.03.006. Epub 2018Jun 29. Review.

PMID:
29983141
Select item 2998121455.

Echocardiography in transcatheter aortic (Core)Valve implantation: Part 2-Transesophageal echocardiography.

Naqvi TZ.

Echocardiography2018 Jul;35(7):1020-1041. doi: 10.1111/echo.14034. Review.

PMID:
29981214
Select item 2998029956.

Impact of patient-specific morphologies on sinus flow stasis in transcatheter aortic valve replacement: An in vitro study.

Hatoum H, Dollery J, Lilly SM, Crestanello J, Dasi LP.

J Thorac Cardiovasc Surg2018 Jun 7. pii: S0022-5223(18)31521-6. doi: 10.1016/j.jtcvs.2018.05.086. [Epub ahead of print]

PMID:
29980299
Select item 2997656857.

Malnutrition and Mortality in Frail and Non-Frail Older Adults Undergoing Aortic Valve Replacement.

Goldfarb M, Lauck S, Webb JG, Asgar AW, Perrault LP, Piazza N, Martucci G, Lachapelle K, Noiseux N, Kim DH, Popma JJ, Lefèvre T, Labinaz M, Lamy A, Peterson MD, Arora RC, Morais JA, Morin JF, Rudski L, Afilalo J; FRAILTY-AVR Investigators .

Circulation2018 Jul 5. pii: CIRCULATIONAHA.118.033887. doi: 10.1161/CIRCULATIONAHA.118.033887. [Epub ahead of print]

PMID:
29976568
Select item 2997636358.

Debris Heterogeneity Across Different Valve Types Captured by a Cerebral Protection System During Transcatheter Aortic Valve Replacement.

Schmidt T, Leon MB, Mehran R, Kuck KH, Alu MC, Braumann RE, Kodali S, Kapadia SR, Linke A, Makkar R, Naber C, Romero ME, Virmani R, Frerker C.

JACC Cardiovasc Interv2018 Jul 9;11(13):1262-1273. doi: 10.1016/j.jcin.2018.03.001.

PMID:
29976363
Select item 2997426459.

A Review of Alternative Access for Transcatheter Aortic Valve Replacement.

Young MN, Singh V, Sakhuja R.

Curr Treat Options Cardiovasc Med2018 Jul 4;20(7):62. doi: 10.1007/s11936-018-0648-5. Review.

PMID:
29974264
Select item 2997123860.

Transcatheter Aortic Valve Replacement and Concomitant Mitral Regurgitation.

Stähli BE, Reinthaler M, Leistner DM, Landmesser U, Lauten A.

Front Cardiovasc Med2018 Jun 19;5:74. doi: 10.3389/fcvm.2018.00074. eCollection 2018. Review.

Select item 2996942761.

Propensity matched comparison of clinical outcomes after transaortic versus transfemoral aortic valve replacement.

Chollet T, Marcheix B, Boudou N, Elbaz M, Campelo-Parada F, Bataille V, Bouisset F, Lairez O, Porterie J, Galinier M, Carrie D, Lhermusier T.

EuroIntervention2018 Jul 3. pii: EIJ-D-18-00168. doi: 10.4244/EIJ-D-18-00168. [Epub ahead of print]

Select item 2996827362.

Alternative access for transcatheter aortic valve replacement in older adults: A collaborative study from France and United States.

Damluji AA, Murman M, Byun S, Moscucci M, Resar JR, Hasan RK, Alfonso CE, Carrillo RG, Williams DB, Kwon CC, Cho PW, Dijos M, Peltan J, Heldman AW, Cohen MG, Leroux L.

Catheter Cardiovasc Interv2018 Jul 3. doi: 10.1002/ccd.27690. [Epub ahead of print]

PMID:
29968273
Select item 2996613163.

Does Aortic Angulation Impact Outcomes in TAVR.

Czarny MJ, Resar JR.

Cardiology2018;140(2):103-105. doi: 10.1159/000489697. Epub 2018 Jul 2. No abstract available.

PMID:
29966131
Select item 2996339164.

Transcaval transcatheter aortic valve replacement: a visual case review.

Muhammad KI, Tokarchik GC.

J Vis Surg2018 May 14;4:102. doi: 10.21037/jovs.2018.04.02. eCollection 2018.

Select item 2996107265.

Aortic Angulation Does Not Impact Outcomes in Self-Expandable or Balloon-Expandable Transcatheter Aortic Valve Replacement.

Elmously A, Gray KD, Truong QA, Burshtein A, Wong SC, de Biasi AR, Worku B, Salemi A.

Cardiology2018;140(2):96-102. doi: 10.1159/000488933. Epub 2018 Jun 29.

PMID:
29961072
Select item 2996075666.

Transcatheter Aortic Valve Replacement in Extremely Large Annuli: (Over)expanding Bioprosthetic Technology to the Limits?

Mehilli J, Jochheim D.

JACC Cardiovasc Interv2018 Jul 23;11(14):1388-1389. doi: 10.1016/j.jcin.2018.05.007. Epub 2018 Jun 27. No abstract available.

PMID:
29960756
Select item 2996075567.

Impact of Aortic Root Anatomy and Geometry on Paravalvular Leak in Transcatheter Aortic Valve Replacement With Extremely Large Annuli Using the Edwards SAPIEN 3 Valve.

Tang GHL, Zaid S, George I, Khalique OK, Abramowitz Y, Maeno Y, Makkar RR, Jilaihawi H, Kamioka N, Thourani VH, Babaliaros V, Webb JG, Htun NM, Attinger-Toller A, Ahmad H, Kaple R, Sharma K, Kozina JA, Kaneko T, Shah P, Hirji SA, Desai ND, Anwaruddin S, Jagasia D, Herrmann HC, Basra SS, Szerlip MA, Mack MJ, Mathur M, Tan CW, Don CW, Sharma R, Gafoor S, Zhang M, Kapadia SR, Mick SL, Krishnaswamy A, Amoroso N, Salemi A, Wong SC, Kini AS, Rodés-Cabau J, Leon MB, Kodali SK.

JACC Cardiovasc Interv2018 Jul 23;11(14):1377-1387. doi: 10.1016/j.jcin.2018.03.034. Epub 2018 Jun 27.

PMID:
29960755
Select item 2995818268.
Select item 2995225269.

Stent fractures after common femoral artery bail-out stenting due to suture device failure in TAVR.

Veulemans V, Afzal S, Ledwig P, Heiss C, Busch L, Sansone R, Soetemann DB, Maier O, Kleinebrecht L, Kelm M, Zeus T, Hellhammer K.

Vasa2018 Jun 28:1-9. doi: 10.1024/0301-1526/a000712. [Epub ahead of print]

PMID:
29952252
Select item 2995183070.

Transcatheter Mitral Valve Replacement: Functional Requirements for Device Design, Bench-Top, and Pre-Clinical Evaluation.

Iyer R, Chalekian A, Lane R, Evans M, Yi S, Morris J.

Cardiovasc Eng Technol2018 Jun 27. doi: 10.1007/s13239-018-0364-z. [Epub ahead of print]

PMID:
29951830
Select item 2994327371.

Gender-dependent association of diabetes mellitus with mortality in patients undergoing transcatheter aortic valve replacement.

Linke A, Schlotter F, Haussig S, Woitek FJ, Stachel G, Adam J, Höllriegel R, Lindner A, Mohr FW, Schuler G, Kiefer P, Leontyev S, Thiele H, Borger MA, Holzhey D, Mangner N.

Clin Res Cardiol2018 Jun 25. doi: 10.1007/s00392-018-1309-0. [Epub ahead of print]

PMID:
29943273
Select item 2994311572.

Transcatheter aortic valve replacement with the 34 mm Medtronic Evolut valve : Early results of single institution experience.

D’Ancona G, Dißmann M, Heinze H, Zohlnhöfer-Momm D, Ince H, Kische S.

Neth Heart J2018 Aug;26(7-8):401-408. doi: 10.1007/s12471-018-1122-4.

Select item 2994136973.

Midterm Outcomes With the Self-Expanding ACURATE neo Aortic Bioprosthesis: The “Bumblebee Paradox” in Transcatheter Aortic Valve Replacement.

Barbanti M, Todaro D.

JACC Cardiovasc Interv2018 Jul 23;11(14):1375-1376. doi: 10.1016/j.jcin.2018.06.004. Epub 2018 Jun 22. No abstract available.

PMID:
29941369
Select item 2993663474.

Atrioventricular and intraventricular block after transcatheter aortic valve implantation.

Lee JJ, Goldschlager N, Mahadevan VS.

J Interv Card Electrophysiol2018 Jun 24. doi: 10.1007/s10840-018-0391-6. [Epub ahead of print]

PMID:
29936634
Select item 2993449375.

Recurrent Unilateral Transudative Pleural Effusion Due to Low Flow, Low Gradient Severe Aortic Stenosis.

Al-Khafaji JF, Taha M, Abdalla AO, Rowan C.

Am J Case Rep2018 Jun 23;19:739-743. doi: 10.12659/AJCR.909448.

Select item 2992964276.

Whose Urgency Is it, Anyway?

Brener SJ.

JACC Cardiovasc Interv2018 Jun 25;11(12):1186-1187. doi: 10.1016/j.jcin.2018.03.035. No abstract available.

PMID:
29929642
Select item 2992964177.

Outcomes Following Urgent/Emergent Transcatheter Aortic Valve Replacement: Insights From the STS/ACC TVT Registry.

Kolte D, Khera S, Vemulapalli S, Dai D, Heo S, Goldsweig AM, Aronow HD, Elmariah S, Inglessis I, Palacios IF, Thourani VH, Sharaf BL, Gordon PC, Abbott JD.

JACC Cardiovasc Interv2018 Jun 25;11(12):1175-1185. doi: 10.1016/j.jcin.2018.03.002. Epub 2018 Mar 11.

PMID:
29929641
Select item 2992963978.

Medium-Term Follow-Up of Early Leaflet Thrombosis After Transcatheter Aortic Valve Replacement.

Ruile P, Minners J, Breitbart P, Schoechlin S, Gick M, Pache G, Neumann FJ, Hein M.

JACC Cardiovasc Interv2018 Jun 25;11(12):1164-1171. doi: 10.1016/j.jcin.2018.04.006.

PMID:
29929639
Select item 2992775879.

Left Subclavian Transcatheter Aortic Valve Replacement Under Combined Interscalene and Pectoralis Nerve Blocks: A Case Series.

Block M, Pitchon DN, Schwenk ES, Ruggiero N, Entwistle J, Goldhammer JE.

A A Pract2018 Jun 18. doi: 10.1213/XAA.0000000000000819. [Epub ahead of print]

PMID:
29927758
Select item 2992620680.

Optimal pre-TAVR annulus sizing in patients with bicuspid aortic valve: area-derived perimeter by CT is the best-correlated measure with intraoperative sizing.

Wang Y, Wang M, Song G, Wang W, Lv B, Wang H, Wu Y.

Eur Radiol2018 Jun 20. doi: 10.1007/s00330-018-5592-y. [Epub ahead of print]

PMID:
29926206
Select item 2992437681.

Immediate improvement of left ventricular mechanics following transcatheter aortic valve replacement.

Lozano Granero VC, Fernández Santos S, Fernández-Golfín C, Plaza Martín M, de la Hera Galarza JM, Faletra FF, Swaans MJ, López-Fernández T, Mesa D, La Canna G, Echeverría García T, Habib G, Martíne Monzonís A, Zamorano Gómez JL.

Cardiol J2018 Jun 20. doi: 10.5603/CJ.a2018.0066. [Epub ahead of print]

Select item 2992312682.

Sex-Specific Considerations in Women with Aortic Stenosis and Outcomes After Transcatheter Aortic Valve Replacement.

Mihos CG, Klassen SL, Yucel E.

Curr Treat Options Cardiovasc Med2018 Jun 19;20(7):52. doi: 10.1007/s11936-018-0651-x. Review.

PMID:
29923126
Select item 2992253583.
Select item 2991587884.

Less pronounced reverse left ventricular remodeling in patients with bicuspid aortic stenosis treated with transcatheter aortic valve replacement compared to tricuspid aortic stenosis.

Xiong TY, Wang X, Li YJ, Liao YB, Zhao ZG, Wei X, Xu YN, Zheng MX, Zhou X, Peng Y, Wei JF, Feng Y, Chen M.

Int J Cardiovasc Imaging2018 Jun 18. doi: 10.1007/s10554-018-1401-6. [Epub ahead of print]

PMID:
29915878
Select item 2991274185.

Predictors of Persistent Tricuspid Regurgitation After Transcatheter Aortic Valve Replacement in Patients With Baseline Tricuspid Regurgitation.

Worku B, Valovska MT, Elmously A, Kampaktsis P, Castillo C, Wong SC, Salemi A.

Innovations (Phila)2018 May/Jun;13(3):190-199. doi: 10.1097/IMI.0000000000000504.

PMID:
29912741
Select item 2991243286.

Transcatheter aortic valve replacement in the setting of left atrial appendage thrombus.

Salemi A, De Micheli A, Aftab A, Elmously A, Chang R, Wong SC, Worku BM.

Interact Cardiovasc Thorac Surg2018 Jun 14. doi: 10.1093/icvts/ivy189. [Epub ahead of print]

PMID:
29912432
Select item 2991133687.

TAVR versus SAVR: Who determines the risk?

Lazar HL.

J Card Surg2018 Jun 17. doi: 10.1111/jocs.13744. [Epub ahead of print] No abstract available.

PMID:
29911336
Select item 2991130788.

Evolving trends in aortic valve replacement: A statewide experience.

Kim KM, Shannon F, Paone G, Lall S, Batra S, Boeve T, DeLucia A, Patel HJ, Theurer PF, He C, Clark MJ, Sultan I, Deeb GM, Prager RL.

J Card Surg2018 Jun 17. doi: 10.1111/jocs.13740. [Epub ahead of print]

PMID:
29911307
Select item 2990896989.

Transcatheter Aortic Valve Replacement on an Aortic Mechanical Valve.

Arzamendi D, Ruiz V, Ramallal R, Alcasena MS, Beunza MT, Larman M.

JACC Cardiovasc Interv2018 Jul 9;11(13):e107-e108. doi: 10.1016/j.jcin.2018.04.046. Epub 2018 Jun 13. No abstract available.

PMID:
29908969
Select item 2990351990.

Transcatheter or surgical treatment of severe aortic stenosis and coronary artery disease: A comparative analysis from the Italian OBSERVANT study.

Barbanti M, Buccheri S, Capodanno D, D’Errigo P, Ranucci M, Rosato S, Santoro G, Fusco D, Tamburino C, Biancari F, Seccareccia F; OBSERVANT Research Group.

Int J Cardiol2018 Jun 7. pii: S0167-5273(17)36915-2. doi: 10.1016/j.ijcard.2018.06.011. [Epub ahead of print]

PMID:
29903519
Select item 2989884891.

Oral anti-Xa anticoagulation after trans-aortic valve implantation for aortic stenosis: The randomized ATLANTIS trial.

Collet JP, Berti S, Cequier A, Van Belle E, Lefevre T, Leprince P, Neumann FJ, Vicaut E, Montalescot G.

Am Heart J2018 Jun;200:44-50. doi: 10.1016/j.ahj.2018.03.008. Epub 2018 Mar 10.

PMID:
29898848
Select item 2989883792.

Utility of an additive frailty tests index score for mortality risk assessment following transcatheter aortic valve replacement.

Steinvil A, Buchanan KD, Kiramijyan S, Bond E, Rogers T, Koifman E, Shults C, Xu L, Torguson R, Okubagzi PG, Pichard AD, Satler LF, Ben-Dor I, Waksman R.

Am Heart J2018 Jun;200:11-16. doi: 10.1016/j.ahj.2018.01.007. Epub 2018 Jan 31.

PMID:
29898837
Select item 2989684793.

Advanced chronic kidney disease: Relationship to outcomes post-TAVR, a meta-analysis.

Makki N, Lilly SM.

Clin Cardiol2018 Jun 12. doi: 10.1002/clc.22993. [Epub ahead of print] Review.

Select item 2989677794.

Comparing outcomes after transcatheter aortic valve replacement in patients with stenotic bicuspid and tricuspid aortic valve: A systematic review and meta-analysis.

Kanjanahattakij N, Horn B, Vutthikraivit W, Biso SM, Ziccardi MR, Lu MLR, Rattanawong P.

Clin Cardiol2018 Jun 12. doi: 10.1002/clc.22992. [Epub ahead of print]

Select item 2989560095.

Stroke and Cardiovascular Outcomes in Patients With Carotid Disease Undergoing Transcatheter Aortic Valve Replacement.

Kochar A, Li Z, Harrison JK, Hughes GC, Thourani VH, Mack MJ, Matsouaka RA, Cohen DJ, Peterson ED, Jones WS, Vemulapalli S.

Circ Cardiovasc Interv2018 Jun;11(6):e006322. doi: 10.1161/CIRCINTERVENTIONS.117.006322.

PMID:
29895600
Select item 2989459496.

Percutaneous access versus surgical cut down for TAVR: Where do we go from here?

Ates I, Cilingiroglu M.

Catheter Cardiovasc Interv2018 Jun;91(7):1363-1364. doi: 10.1002/ccd.27653.

PMID:
29894594
Select item 2989341797.

Inadvertent pacemaker lead dislodgement.

Eulert-Grehn JJ, Schmidt G, Kempfert J, Starck C.

Pacing Clin Electrophysiol2018 Jun 12. doi: 10.1111/pace.13412. [Epub ahead of print]

PMID:
29893417
Select item 2988800998.

Successful Coronary Protection during TAVI in Heavily Calcified Aortic Leaflets in Patient with Short and Low Left Coronary System.

Kabach M, Alrifai A, Lovitz L, Rothenberg M, Faber C, Nores M.

Case Rep Cardiol2018 May 14;2018:2758170. doi: 10.1155/2018/2758170. eCollection 2018.

Select item 2988746499.

Role of T2 mapping in left ventricular reverse remodeling after TAVR.

Gastl M, Behm P, Haberkorn S, Holzbach L, Veulemans V, Jacoby C, Schnackenburg B, Zeus T, Kelm M, Bönner F.

Int J Cardiol2018 Sep 1;266:262-268. doi: 10.1016/j.ijcard.2018.02.029.

PMID:
29887464
Select item 29885699100.

Early changes in N-terminal pro-B-type natriuretic peptide levels after transcatheter aortic valve replacement and its impact on long-term mortality.

Liebetrau C, Gaede L, Kim WK, Arsalan M, Blumenstein JM, Fischer-Rasokat U, Wolter JS, Kriechbaum S, Huber MT, van Linden A, Berkowitsch A, Dörr O, Nef H, Hamm CW, Walther T, Möllmann H.

Int J Cardiol2018 Aug 15;265:40-46. doi: 10.1016/j.ijcard.2018.02.037.

PMID:
29885699

Read Full Post »


Aortic Stenosis (AS): Managed Surgically by Transcatheter Aortic Valve Replacement (TAVR) – Search Results for “TAVR” on NIH.GOV website, Top 16 pages

Reporter: Aviva Lev-Ari, PhD, RN

 

UPDATED on 9/24/2018

Sapien 3, CoreValve Evolut R on Par for Aortic Stenosis

Head-to-head trial also shows local, general anesthesia outcomes similar

by Ashley Lyles, Staff Writer, MedPage Today

  • This article is a collaboration between MedPage Today® and:

    Medpage Today

SAN DIEGO — Transfemoral transcatheter aortic valve replacement (TAVR) with the balloon-expandable Edwards Sapien 3 valve yields the same early outcomes as the self-expanding CoreValve Evolut R, regardless of anesthesia strategy, a two-by-two randomized trial showed.

In the valve comparison, the primary endpoint of all-cause mortality, stroke, moderate or severe prosthetic valve regurgitation, and permanent pacemaker implantation at 30 days met criteria for equivalence, with a composite rate of 27.2% with Evolut R and 26.1% with Sapien 3, Holger Thiele, MD, of University Hospital in Leipzig, Germany, reported here at the Transcatheter Cardiovascular Therapeutics meeting.

The researchers also evaluated the effects of anesthesia used during these procedures and found no significant difference. The composite endpoint at 30 days came out 27.0% for local anesthesia and 25.5% for general anesthesia.

“The SOLVE-TAVI trial is the first adequately powered randomized trial comparing local versus general anesthesia in patients with symptomatic aortic valve stenosis undergoing TAVR,” said Thiele in a press release. “Results indicate that local anesthesia is both safe and effective and may be a good option for those patients undergoing TAVR with an intermediate or high surgical risk.”

In the majority of aortic stenosis cases, it doesn’t matter which valve you choose, although there are still some cases, like heavy calcification, when it may be better to choose one valve over the other, noted panel discussant Molly Szerlip, MD, of Baylor Scott & White The Heart Group in McKinney, Texas.

The researchers evaluated 447 patients who were receiving care at German medical centers for severe symptomatic aortic stenosis and were at an intermediate- to high-surgical risk. The patients were randomized to have the Sapien 3 valve or CoreValve Evolut R and to either receive general or local anesthesia with conscious sedation.

The individual valve strategy findings again showed equivalence without superiority between Evolut R and Sapien 3 for mortality (2.8% vs 2.3%) and moderate or severe valve regurgitation (1.9% vs 1.4%). But for stroke Evolut R came out superior (0.5% vs 4.7%), and the two didn’t meet criteria for equivalence on pacemaker implantation (22.9% vs 19.0%, P=0.06 for equivalence).

“The rate of relevant valve regurgitation was low whereas permanent pacemaker rates are still relatively high,” the researchers wrote.

The anesthesia comparison endpoints all met the criteria for equivalence without superiority of general anesthesia over local anesthesia:

  • Morality (2.3% vs 2.8%)
  • Stroke (2.8% vs 2.4%)
  • Myocardial infarction (both 0.5%)
  • Infection requiring antibiotics (both 21.0%)
  • Acute kidney injury (9.2% vs 8.9%)

SOURCE

https://www.medpagetoday.com/meetingcoverage/tct/75262?xid=nl_mpt_ACC_Reporter_2018-09-23&eun=g5099207d2r

 

The concept of transcatheter balloon expandable valves was first introduced in the 1980s by a Danish researcher by the name of H. R. Anderson who began testing this idea on pigs. In 2002, Dr. Alain Cribier performed the first successful percutaneous aortic valve replacement on an inoperable patient. The first approval of TAVR for the indication of severe AS in prohibitive risk patients came in 2011. In 2012, the FDA approved TAVR in patients at high surgical risk. In 2015 the indication was expanded to include “valve-in-valve” procedure for failed surgical bioprosthetic valves. Most recently, in 2016 the FDA approved the SAPIEN valve for use in patients with severe AS at intermediate risk.

SOURCE

https://www.ncbi.nlm.nih.gov/pubmed/28613729

 

Critical care management of patients following …

Transcatheter aortic valve replacement (TAVR) is rapidly gaining popularity as a technique to surgically manage aortic stenosis (AS) in high risk …

Imaging in Transcatheter Aortic Valve Replacement (TAVR …

Transcatheter aortic valve replacement (TAVR) is a novel technique developed in the last decade to treat severe aortic stenosis in patients who are …

TAVR and SAVR: Current Treatment of Aortic Stenosis

Transcatheter aortic valve replacement (TAVR) was approved in the United States in late 2011, providing a critically needed alternative therapy for …

Transcatheter Aortic Valve Replacement: Design, Clinical …

Transcatheter aortic valve replacement (TAVR) is a new technology that recently has been shown to improve survival and quality of life in patients …

Cost-Effectiveness Analysis of TAVR

Transcather aortic valve replacement (TAVR) has rapidly gained worldwide acceptance for treating very high-risk patients with symptomatic severe …

Clinical Studies Assessing Transcatheter Aortic Valve …

Extreme-Risk or Inoperable Patients for sAVR. Early clinical evaluation of TAVR included patients deemed unsuitable for sAVR. The logistic Euroscore …

Mitral Valve Surgery: Current Minimally Invasive and …

Minimally Invasive Mitral Valve Repair or Replacement. Most MV pathology can be treated with minimally invasive, … As we learned from the TAVR …

Transcatheter (TAVR) versus surgical (AVR) aortic valve …

The risk in the early phase was higher after TAVR than AVR, and in the TAVR arm in patients with a smaller aortic valve area index. In the late risk …

Procedure makes heart valve replacement safer for high-risk patients

4 months ago – Scientists developed a novel technique that prevents a rare but often fatal complication that can arise during a heart valve procedure called …

Sedation or general anesthesia for transcatheter aortic …

Transfemoral transcatheter aortic valve implantation (TAVI) is nowadays a routine therapy for elderly patients with severe aortic stenosis (AS) and …

Transcatheter aortic valve replacement: outcomes of …

Transcatheter aortic valve replacement: outcomes of patients with moderate or severe mitral regurgitation. Toggweiler S(1), … One year after TAVR …

Outcomes in Transcatheter Aortic Valve Replacement for …

BACKGROUND: Transcatheter aortic valve replacement (TAVR) is being increasingly performed in patients with bicuspid aortic valve stenosis (AS).

New method for performing aortic valve replacement proves …

Researchers at the National Institutes of Health have developed a new, less invasive way to perform transcatheter aortic valve replacement (TAVR), a …

Acquired Aorto-Right Ventricular Fistula following …

Transcatheter aortic valve replacement (TAVR) techniques are rapidly evolving, and results of published trials suggest that TAVR is emerging as the …

Post Transapical Aortic Valve Replacement (TAVR …

A 63-year-old female presented to the emergency department with complaints of her “heart beating out of my chest,” palpitations, and shortness of …

Surgical or Transcatheter Aortic-Valve Replacement in …

Surgical or Transcatheter Aortic-Valve Replacement in Intermediate-Risk Patients. … Although transcatheter aortic-valve replacement (TAVR) …

Transcatheter aortic valve replacement versus surgical …

Transcatheter aortic valve replacement versus surgical valve replacement in intermediate-risk patients: a propensity score analysis. Thourani VH(1) …

Transcatheter aortic valve replacement (TAVR): access …

Ramlawi B(1), Anaya-Ayala JE, Reardon MJ. Author information: (1)Methodist DeBakey Heart & Vascular Center, The Methodist Hospital, Houston, Texas …

Simulation of Transcatheter Aortic Valve Replacement in …

Simulation of Transcatheter Aortic Valve Replacement in patient-specific aortic roots: … Transcatheter aortic valve replacement (TAVR), …

Simulation of Transcatheter Aortic Valve Replacement in …

Simulation of Transcatheter Aortic Valve Replacement in patient-specific aortic roots: … Transcatheter aortic valve replacement (TAVR), …

Transcatheter Aortic Valve Replacement Versus Surgery in …

The objective of this study was to compare outcomes in women after surgical aortic valve replacement … transcatheter aortic valve replacement (TAVR) …

Lederman Lab – NHLBI Cardiovascular Intervention Program

ledermanlab.nhlbi.nih.gov/

Transcaval TAVR was developed at the NHLBI Cardiovascular Intervention Program and applied to patient care in collaboration with Dr. Adam Greenbaum at …

Functional status and quality of life after transcatheter …

Kim CA, Rasania SP, Afilalo J, Popma JJ, Lipsitz LA, Kim DH. BACKGROUND: The functional and quality-of-life benefits of transcatheter aortic valve …

One-Year Outcomes of Transcatheter Aortic Valve …

1. Ann Thorac Surg. 2017 May;103(5):1392-1398. doi: 10.1016/j.athoracsur.2016.11.061. Epub 2017 Feb 24. One-Year Outcomes of Transcatheter Aortic …

Local versus general anesthesia for transcatheter aortic …

Now randomized trials are needed for further evaluation of MAC in the setting of TAVR. PMCID: PMC4022332 PMID: 24612945 [PubMed – indexed for MEDLINE]

Predictors and clinical outcomes of permanent pacemaker …

CONCLUSIONS: PPM was required in 8.8% of patients without prior PPM who underwent TAVR with a balloon-expandable valve in the PARTNER trial and …

Transcatheter aortic valve replacement program development …

TAVR programs require data management strategies to facilitate and monitor program growth, support program evaluation, and meet the requirements for …

New technique makes heart valve replacement safer for some …

Lederman explained that during TAVR, the surgeon places a catheter inside the heart and uses a balloon to open a new valve inside the aortic valve.

Minimally invasive aortic valve replacement using the …

The term “sutureless aortic valve” (su-AV) describes a type of valve which facilitates anchoring of bioprostheses in the aortic position without use …

Use of extracorporeal membrane oxygenation in complicated …

1. Gen Thorac Cardiovasc Surg. 2017 Feb 24. doi: 10.1007/s11748-017-0757-1. [Epub ahead of print] Use of extracorporeal membrane oxygenation in …

Reoperative aortic valve replacement through upper …

Reoperative aortic valve replacement (AVR) has become increasingly common . … but who may not be considered eligible for TAVR procedure.

MRI evaluation prior to Transcatheter Aortic Valve …

MRI evaluation prior to Transcatheter Aortic Valve Implantation … Transcatheter Aortic Valve Implantation (TAVI) … imaging for TAVR assessment in …

Impact of New-Onset Left Bundle Branch Block and …

New-onset LBBB post-TAVR was associated with a higher risk of PPI (risk ratio [RR], 2.18; 95% confidence interval [CI], 1.28-3.70) and cardiac death …

Migration of the transcatheter valve into the left ventricle

Transcatheter valves can embolize into the aorta if the valve is malpositioned too high or, less commonly, migrate into the left ventricle when the …

Transcarotid Transcatheter Aortic Valve Replacement …

All patients were unsuitable for transfemoral TAVR due to severe peripheral vascular disease. An MIS was undertaken in 29.8% (n = 52) …

The transaortic approach for transcatheter aortic valve …

The transaortic approach for transcatheter aortic valve replacement: initial clinical experience in the United States. Lardizabal JA(1), O’Neill BP …

Transcatheter Aortic Valve Replacement: The New Standard …

Transcatheter Aortic Valve Replacement: The … The aim of this study was to assess how the introduction of transcatheter aortic valve replacement (TA …

Minimally invasive aortic valve surgery: state of the art …

Minimally invasive aortic valve replacement (MIAVR) is defined as an aortic valve replacement (AVR) procedure that involves a small chest wall …

Prognostic impact of pulmonary artery systolic pressure in …

Prognostic impact of pulmonary artery systolic pressure in patients undergoing transcatheter aortic valve … TAVR was associated with a decrease in …

Transcatheter Aortic Valve Replacement is Associated with …

This meta-analysis aims to assess the differential outcomes of TAVR and SAVR in patients enrolled in published randomised controlled trials (RCTs).

Aspirin Versus Aspirin Plus Clopidogrel as Antithrombotic …

There were no differences between groups in valve hemodynamic status post-TAVR. CONCLUSIONS: This small trial showed that SAPT (vs. DAPT) …

Upper gastrointestinal bleeding following transcatheter …

Upper gastrointestinal bleeding following transcatheter aortic valve replacement: A retrospective analysis. Stanger DE(1), … (TAVR). BACKGROUND: …

Computed tomography-based sizing recommendations for …

Consecutive patients (n = 120) underwent CT before TAVR with balloon-expandable valves sized by transesophageal echocardiography (TEE) …

European experience and perspectives on transcatheter …

European experience and perspectives on transcatheter aortic valve replacement. Davies WR(1), Thomas MR(2).

[PDF] Mandatory Reporting of Clinical Trial Identifier Numbers …

accrualnet.cancer.gov/sites/accrualnet.cancer.gov/files/Mandatory%20Reporting%20of%20Clinical%20Trial%20Identifier%20FAQs.pdf

Mandatory Reporting of Clinical Trial Identifier Numbers on Claims . Q: Do organizations bill Medicare for all services related to the clinical trial …

Transcatheter Aortic Valve Replacement: Imaging Techniques …

Transcatheter Aortic Valve Replacement: Imaging Techniques for Aortic Root Sizing. Wichmann JL(1), Varga-Szemes A, Suranyi P, Bayer RR 2nd, Litwin SE …

Transcatheter Aortic Valve Thrombosis: Incidence …

METHODS: Among 460 consecutive patients who underwent TAVR with the Edwards Sapien XT or Sapien 3 (Edwards Lifesciences, Irvine, California) THV, …

Sutureless aortic valve replacement – PubMed Central (PMC)

Given its recent developments, the majority of evidence regarding sutureless aortic valve replacement (SU-AVR) is limited to observational studies …

Comparison of balloon-expandable vs self-expandable valves …

Comparison of balloon-expandable vs self-expandable valves in patients undergoing transcatheter aortic valvereplacement: … (TAVR) is an effective …

Geometric changes in ventriculoaortic complex after …

Geometric changes in ventriculoaortic complex after transcatheter aortic valve replacement and its association … The post-TAVR AoA area/pre-TAVR AoA …

Acute and 30-Day Outcomes in Women After TAVR: Results …

Randomized assessment of TAVR versus surgical aortic valve replacement in intermediate risk women is warranted to determine the optimal strategy.

Should We Perform Carotid Doppler Screening Before …

Should We Perform Carotid Doppler Screening Before Surgical or Transcatheter Aortic Valve Replacement? … (TAVR) between January 2007 and August …

Transcatheter Versus Surgical Aortic Valve Replacement in …

BACKGROUND: Transcatheter aortic valve replacement (TAVR) is an option in certain high-risk surgical patients with severe aortic valve stenosis.

Risk stratification and clinical pathways to optimize …

Risk stratification and clinical pathways to optimize length of stay after … We evaluated standardized TAVRoutcomes and length of stay according to …

Use of imaging for procedural guidance during …

1. Curr Opin Cardiol. 2013 Sep;28(5):512-7. doi: 10.1097/HCO.0b013e3283632b5e. Use of imaging for procedural guidance during transcatheter aortic …

Serial Changes in Cognitive Function Following …

Serial Changes in Cognitive Function Following Transcatheter Aortic Valve Replacement. Auffret V(1), Campelo-Parada F(1), Regueiro A(1), …

Acute kidney injury after transcatheter aortic valve …

Acute kidney injury after transcatheter aortic valve replacement: a systematic review and meta-analysis. Thongprayoon C(1), Cheungpasitporn W, Srivali …

Aortic valve replacement – PubMed Health

Transcatheter aortic valve replacement (TAVR), sometimes called transcatheter aortic valve implantation (TAVI), was developed as an alternative for …

Costs of periprocedural complications in patients treated …

Costs of periprocedural complications in patients treated with transcatheter aortic valve replacement: … Renal failure and the need for repeat TAVR …

Trial design: Rivaroxaban for the prevention of major …

The direct factor Xa inhibitor rivaroxaban may potentially reduce TAVR-related thrombotic complications and premature valve failure. DESIGN: GALILEO …

Expandable sheath for transfemoral transcatheter aortic …

Expandable sheath for transfemoral transcatheter aortic valve replacement: procedural outcomes and complications. Borz B(1), Durand E, Tron C, …

Direct Aortic Access Transcatheter Aortic Valve …

Direct Aortic Access Transcatheter Aortic Valve Replacement: Three-Dimensional Computed Tomography Planning and Real … was selected for DA-TAVR …

The impact of frailty on outcomes after cardiac surgery: a …

1. J Thorac Cardiovasc Surg. 2014 Dec;148(6):3110-7. doi: 10.1016/j.jtcvs.2014.07.087. Epub 2014 Aug 7. The impact of frailty on outcomes after …

Establishment of a transcatheter aortic valve program and …

Establishment of a transcatheter aortic valve program and heart valve team at a Veterans Affairs facility. … (TAVR) program.

Echocardiographic determinants of LV functional …

Echocardiographic determinants of LV functional improvement after transcatheter aortic valve replacement. … Transcatheter aortic valve replacement ( …

CT in transcatheter aortic valve replacement.

CT in transcatheter aortic valve replacement. … the rapidly emerging role of CT in the context of transcatheter aortic valve replacement will be …

Transcatheter Aortic Valve Replacement for the Treatment …

Transcatheter Aortic Valve Replacement for the … This study sought to summarize available evidence on transcatheter aortic valve replacement (TAVR) …

Valvular performance and aortic regurgitation following …

End points were post-TAVR moderate to severe AR and paravalvular AR, effective orifice area (EOA), mean trans-aortic pressure gradient (MPG), …

Annual Outcomes With Transcatheter Valve Therapy: From the …

Annual Outcomes With Transcatheter Valve Therapy: From the STS/ACC TVT Registry. Holmes DR Jr, Nishimura RA, Grover FL, Brindis RG, Carroll JD …

The impact of live case transmission on patient outcomes …

The impact of live case transmission on patient outcomes during transcatheter aortic valve replacement: … Data support the notion that live …

Review of Major Registries and Clinical Trials of Late …

Review of Major Registries and Clinical Trials of Late Outcomes After Transcatheter … Final studies were selected irrespective of the type of TAVR …

Trans-subclavian aortic valve replacement with various …

Trans-subclavian aortic valve replacement with various bioprosthetic valves: Single-center experience. Kasapkara HA(1), Aslan AN(2), Ayhan H(1), …

Vascular complications post-transcatheter aortic valve …

Vascular complications post-transcatheter aortic valve procedures. Mangla A(1), Gupta S(2). Author information: (1)Division of Cardiology, Department …

[Monitoring of haemodynamics and function of the aortic …

[Monitoring of haemodynamics and function of the aortic prosthesis during transcatheter aortic valve replacement]. [Article in Russian]

Midregional Proadrenomedullin Improves Risk Stratification …

Midregional Proadrenomedullin Improves Risk Stratification beyond Surgical Risk Scores in Patients Undergoing Transcatheter Aortic Valve … (TAVR …

Midregional Proadrenomedullin Improves Risk Stratification …

Midregional Proadrenomedullin Improves Risk Stratification beyond Surgical Risk Scores in Patients Undergoing Transcatheter Aortic Valve … (TAVR …

Dual Versus Single Antiplatelet Regimen With or Without …

Dual Versus Single Antiplatelet Regimen With or Without Anticoagulation in Transcatheter Aortic Valve … (TAVR), with dual antiplatelet therapy …

Impact of baseline mitral regurgitation on short- and long …

Impact of baseline mitral regurgitation on short- and long-term outcomes following transcatheter aortic … before the index TAVR procedure was …

TAVRassociated prosthetic valve infective endocarditis …

TAVRassociated prosthetic valve infective endocarditis: results of a large, multicenter registry. Latib A, Naim C, De Bonis M, Sinning JM, …

Mechanisms of Heart Block after Transcatheter Aortic Valve …

Consequently, patients undergoing TAVR are prone to peri-procedural complications including cardiac conduction disturbances, which is the focus of …

JACC. Cardiovascular Imaging – Journals – NCBI

JACC. Cardiovascular Imaging journal page at PubMed Journals. Published by Elsevier

Short-Term Outcomes with Direct Aortic Access for …

Short-Term Outcomes with Direct Aortic Access for Transcatheter Aortic Valve Replacement. Ramlawi B, Abu Saleh WK, Jabbari OA, Barker C, Lin C, … (T …

Impact of patient-prosthesis mismatch after transcatheter …

Impact of patient-prosthesis mismatch after transcatheter aortic valve-in-valve implantation in degenerated bioprostheses. Seiffert M(1), Conradi L …

Extent and distribution of calcification of both the …

AR grade 2 to 4 assessed by the method of Sellers immediately after TAVR device implantation was observed in 55 patients (31%). Multivariate …

Safety, Feasibility, and Hemodynamic Effects of Mild …

Safety, Feasibility, and Hemodynamic Effects of Mild Hypothermia in Transcatheter Aortic Valve Replacement: The TAVR … feasibility, and hemodynamic …

Transcatheter aortic valve implantation: anesthetic …

Transcatheter aortic valve implantation: anesthetic considerations. Billings FT 4th(1), Kodali SK, Shanewise JS. Author information: (1)Departments of …

RFA-HL-19-009: Cardiothoracic Surgical Trials Network …

grants.nih.gov/grants/guide/rfa-files/RFA-HL-19-009.html

Bicuspid aortic valve disease has been excluded from TAVR pivotal trials, but TAVR is increasingly used in this population, despite …

www.ncbi.nlm.nih.gov

Moved Permanently. The document has moved here.

Outcome comparison of African-American and Caucasian …

METHODS: Consecutive patients who underwent TAVR were included in this analysis. Patients’ baseline characteristics, procedural data, …

Incidence and predictors of permanent pacemaker …

Incidence and predictors of permanent pacemaker implantation following treatment with the repositionable Lotus™ transcatheter aortic valve.

Effect of Hospital Volume on Outcomes of Transcatheter …

Effect of Hospital Volume on Outcomes of Transcatheter Aortic Valve Implantation. Badheka AO(1), Patel NJ(2), Panaich SS(3), Patel SV(4), …

Aortic valve sizer for TAVR | NIH 3D Print Exchange

3dprint.nih.gov/discover/3dpx-007958

This sizer is designed to simulate the insertion of heart valve prosthetics into 3d printed patient phantoms. It is loosely based on the size …

Health Topics | National Heart, Lung, and Blood Institute …

Materials for patients and health professionals on health topics related to overweight and obesity, heart, lung, blood, and sleep disorders.

DailyMed – ASPIRIN 81MG ADULT LOW DOSE- aspirin tablet …

dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14d010fb-c4a1-4c3d-942f-58719727bfc0

ASPIRIN 81MG ADULT LOW DOSE- aspirin tablet, delayed release . To receive this label RSS feed. Copy the URL below and paste it into your RSS Reader …

Incidence and predictors of permanent pacemaker …

Incidence and predictors of permanent pacemaker implantation following treatment with the repositionable Lotus™ transcatheter aortic valve.

Aortic valve sizer for TAVR | NIH 3D Print Exchange

3dprint.nih.gov/discover/3dpx-007958

This sizer is designed to simulate the insertion of heart valve prosthetics into 3d printed patient phantoms. It is loosely based on the size …

Transcatheter Aortic Valve Replacement in Severe Aortic …

1. Transcatheter Aortic Valve Replacement in Severe Aortic Stenosis: A Review of Comparative Durability and Clinical Effectiveness Beyond 12 Months …

Sigmoid Septum and Balloon-Expandable Transcatheter Aortic …

de Biasi AR, Worku B, Skubas NJ, Salemi A. Transcatheter aortic valve replacement (TAVR) continues to garner considerable attention, especially as the …

Intra- and Inter-Observer Reproducibility of Transcatheter …

Intra- and Inter-Observer Reproducibility of Transcatheter Aortic Valve Replacement Planning Measurements by Multidetector … of the pre-TAVR …

www.ncbi.nlm.nih.gov

Moved Permanently. The document has moved here.

Transthoracic Echocardiography to Assess Aortic …

Transthoracic Echocardiography to Assess Aortic Regurgitation after TAVRA Comparison with Periprocedural Transesophageal Echocardiography.

Procedural Experience for Transcatheter Aortic Valve …

Procedural Experience for Transcatheter Aortic Valve Replacement and Relation to Outcomes: The STS/ACC TVT Registry. Carroll JD(1), Vemulapalli S(2) …

A comprehensive review of the PARTNER trial.

Svensson LG(1), Tuzcu M, Kapadia S, Blackstone EH, Roselli EE, Gillinov AM, Sabik JF 3rd, Lytle BW. Author information: (1)Department of Thoracic and …

TCT-697 Comparison of Outcomes of Transcatheter Aortic …

TCT-697 Comparison of Outcomes of Transcatheter Aortic Valve Replacement plus Percutaneous Coronary Intervention versus Transcatheter Aortic Valve …

Combined rotational atherectomy and aortic balloon …

Combined rotational atherectomy and aortic balloon valvuloplasty as a bridge to transcatheter aortic valve replacement. Ali O(1), Marmagkiolis K(2) …

Updated standardized endpoint definitions for …

1. Eur J Cardiothorac Surg. 2012 Nov;42(5):S45-60. doi: 10.1093/ejcts/ezs533. Epub 2012 Oct 1. Updated standardized endpoint definitions for …

Clinical outcomes after transcatheter aortic valve …

CONCLUSIONS: VARC definitions have already been used by the TAVR clinical research community, establishing a new standard for reporting clinical …

2012 ACCF/AATS/SCAI/STS expert consensus document on …

2012 ACCF/AATS/SCAI/STS expert consensus document on transcatheter aortic valve replacement. Holmes DR Jr, Mack MJ, Kaul S, Agnihotri A, Alexander KP …

Combined rotational atherectomy and aortic balloon …

Combined rotational atherectomy and aortic balloon valvuloplasty as a bridge to transcatheter aortic valve replacement. Ali O(1), Marmagkiolis K(2) …

Clinical outcomes after transcatheter aortic valve …

CONCLUSIONS: VARC definitions have already been used by the TAVR clinical research community, establishing a new standard for reporting clinical …

TAVR MVR – PubMed Result – ncbi.nlm.nih.gov

1: Grover FL, Vemulapalli S, Carroll JD, Edwards FH, Mack MJ, Thourani VH, Brindis RG, Shahian DM, Ruiz CE, Jacobs JP, Hanzel G, Bavaria JE, Tuzcu EM …

Aortic valve calcium scoring is a predictor of …

Aortic valve calcium scoring is a predictor of paravalvular aortic regurgitation after transcatheter aortic valve implantation

Transcatheter Aortic Valve-in-Valve Replacement Instead of …

Díez JG, Schechter M, Dougherty KG, Preventza O, Coselli JS. Transcatheter aortic valve replacement (TAVR) is a well-established method for replacing …

Coronary Calcium Scan | National Heart, Lung, and Blood …

Buildup of calcium, or calcifications, are a sign of atherosclerosis, coronary heart disease, or coronary microvascular disease. A coronary calcium …

An update on transcatheter aortic valve replacement.

An update on transcatheter aortic valve replacement. … Before the development of transcatheter aortic valve replacement (TAVR … and noninferiority …

The Iowa Model of Evidence-Based Practice to Promote …

The Iowa Model of Evidence-Based Practice to Promote Quality Care: an illustrated example in oncology nursing. Brown CG(1). Author information: …

Two-Year Outcomes in Patients With Severe Aortic Valve …

There was no difference in all-cause mortality at 2 years between TAVR and SAVR (8.0% versus 9.8%, respectively; P=0.54) or cardiovascular mortality …

Home – PubMed – NCBI

PubMed comprises more than 28 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include …

Integrated 3D Echo-X-Ray navigation to predict optimal …

Integrated 3D Echo-X-Ray navigation to predict optimal angiographic deployment projections for TAVR. Kim MS, Bracken J, Nijhof N, Salcedo EE, Quaife …

Cardiac rehabilitation after transcatheter aortic valve …

Cardiac rehabilitation after transcatheter aortic valve implantation compared to patients after valve replacement. Tarro Genta F(1), Tidu M, Bouslenko …

TAVR | NIH 3D Print Exchange

3dprint.nih.gov/discover/tavr

TAVR. Discover > TAVR. 3DPX-007958 Aortic valve sizer for TAVR ahmedhosny. TAVR, aortic valve, sapienXT, heart valve, sizer, Prosthetic. Discover 3D …

www.ncbi.nlm.nih.gov

Moved Permanently. The document has moved here.

Imaging Pandora’s Box: incidental findings in elderly …

Imaging Pandora’s Box: incidental findings in elderly patients evaluated for transcatheter aortic valve replacement. Orme NM(1), Wright TC(2), Harmon …

fascia iliaca compartment block – PubMed – NCBI

TCT-753 Fascia Iliaca Compartment Block (FICB) and None to Light Sedation as an Alternative Minimalist Approach to Sedation for Patients Undergoing …

Stents | National Heart, Lung, and Blood Institute (NHLBI)

For the Coronary Arteries. Doctors may use stents to treat coronary heart disease (CHD). CHD is a disease in which a waxy substance called plaque …

TAVR | NIH 3D Print Exchange

3dprint.nih.gov/discover/tavr

TAVR. Discover > TAVR. 3DPX-007958 Aortic valve sizer for TAVR ahmedhosny. TAVR, aortic valve, sapienXT, heart valve, sizer, Prosthetic. Discover 3D …

Imaging Pandora’s Box: incidental findings in elderly …

Imaging Pandora’s Box: incidental findings in elderly patients evaluated for transcatheter aortic valve replacement. Orme NM(1), Wright TC(2), Harmon …

Transcatheter Aortic Valve Implantation Within Degenerated …

Transcatheter Aortic Valve Implantation Within Degenerated Aortic Surgical Bioprostheses: PARTNER 2 Valve-in-Valve Registry. Webb JG(1), Mack MJ(2) …

[PDF] Transmural” catheter interventions for congenital and …

demystifyingmedicine.od.nih.gov/dm16/m03d22/DM-LedermanRJ.pdf

Transmural” catheter interventions for congenital and structural heart disease … For TAVR, TEVAR, pVAD, etc, when 6-9 mm femoral artery sheaths …

Leaflet Thrombosis in Surgically Explanted or Post-Mortem …

1. JACC Cardiovasc Imaging. 2017 Jan;10(1):82-85. doi: 10.1016/j.jcmg.2016.11.009. Leaflet Thrombosis in Surgically Explanted or Post-Mortem TAVR Valv …

Diagnostic accuracy of multidetector computed tomography …

Diagnostic accuracy of multidetector computed tomography coronary angiography in 325 consecutive patients referred for transcatheter aortic valve …

Transcatheter aortic valve implantation in bicuspid anatomy.

Zhao ZG(1), Jilaihawi H(2), Feng Y(1), Chen M(1). Author information: (1)Department of Cardiology, West China Hospital, Sichuan University, 37 Guoxue …

www.ncbi.nlm.nih.gov

Moved Permanently. The document has moved here.

Platelet activation is less enhanced in the new balloon …

Stroke and thromboembolic events after transfemoral aortic valve replacement (TAVR) continue to be a problem. The aim of our study was to compare …

Discover 3D Models | NIH 3D Print Exchange

3dprint.nih.gov/discover?terms=&field_model_category_tag_tid%5B0%5D=93&field_model_license_nid=All&sort_by=created&sort_order=DESC&items_per_page=24&page=2

Discover 3D Models . Back To Top. Search . Enter terms, … 3DPX-007958 Aortic valve sizer for TAVR. ahmedhosny. 3DPX-007884 Fly Pad. Joyner Cruz …

Beyond PARTNER: appraising the evolving trends and …

Beyond PARTNER: appraising the evolving trends and outcomes in transcatheter aortic valve replacement. … TAVR may become an alternative to surgical …

1-Year Outcomes With the Fully Repositionable and …

1. JACC Cardiovasc Interv. 2016 Feb 22;9(4):376-384. doi: 10.1016/j.jcin.2015.10.024. 1-Year Outcomes With the Fully Repositionable and Retrievable …

www.ncbi.nlm.nih.gov

Moved Permanently. The document has moved here.

Beyond PARTNER: appraising the evolving trends and …

Beyond PARTNER: appraising the evolving trends and outcomes in transcatheter aortic valve replacement. … TAVR may become an alternative to surgical …

Echocardiographic imaging of procedural complications …

Echocardiographic imaging of procedural complications during self-expandable transcatheter aortic valve replacement. Hahn RT(1), Gillam LD(2), Little …

Digest – The NIH Record – November 18, 2016

nihrecord.nih.gov/newsletters/2016/11_18_2016/digest.htm

For about 85 percent of patients with this condition, doctors typically perform TAVR through the femoral artery in the leg. But for the other 15 …

Electrocardiographic changes and clinical outcomes after …

Gutiérrez M(1), Rodés-Cabau J, Bagur R, Doyle D, DeLarochellière R, Bergeron S, Lemieux J, Villeneuve J, Côté M, Bertrand OF, Poirier P, Clavel MA …

Coronary Artery Bypass Grafting | National Heart, Lung …

Coronary artery bypass grafting (CABG) is a type of surgery that improves blood flow to the heart. Surgeons use CABG to treat people who have severe …

Heart Surgery | National Heart, Lung, and Blood Institute …

Heart surgery is done to correct problems with the heart. Many heart surgeries are done each year in the United States for various heart problems. The …

Aspirin-clopidogrel no better than aspirin alone for …

NIH study also shows that overall stroke risk is down from 10 years ago. Aspirin combined with the antiplatelet drug clopidogrel is no better than asp …

Heart Valve Disease | National Heart, Lung, and Blood …

Heart valve disease occurs if one or more of your heart valves don’t work well. The heart has four valves: the tricuspid, … (TAVR). For this …

The Odyssey of TAVR from concept to clinical reality.

1. Tex Heart Inst J. 2014 Apr 1;41(2):125-30. doi: 10.14503/THIJ-14-4137. eCollection 2014. The Odyssey of TAVR from concept to clinical reality.

Echo Doppler Estimation of Pulmonary Capillary Wedge …

Echo Doppler Estimation of Pulmonary Capillary Wedge Pressure in Patients with … (TAVR) has become a … Noninvasive quantification of pulmonary …

Aspirin-clopidogrel no better than aspirin alone for …

NIH study also shows that overall stroke risk is down from 10 years ago. Aspirin combined with the antiplatelet drug clopidogrel is no better than asp …

Could late enhancement and need for permanent pacemaker …

Could late enhancement and need for permanent pacemaker implantation in patients undergoing TAVR be explained by undiagnosed transthyretin cardiac …

Diabetes mellitus is associated with increased acute …

However, there are conflicting data on the impact of DM on outcomes of transcatheter aortic valve replacement (TAVR). HYPOTHESIS: …

Cardiac Catheterization | National Heart, Lung, and Blood …

Cardiac catheterization (KATH-eh-ter-ih-ZA-shun) is a medical procedure used to diagnose and treat some heart conditions. A long, thin, flexible tube …

The National Institutes of Health (NIH) Consensus …

consensus.nih.gov/1984/1984FrozenPlasma045html.htm

Fresh Frozen Plasma: Indications and Risks. National Institutes of Health Consensus Development Conference Statement September 24-26, 1984

Successful repair of aortic annulus rupture during …

Successful repair of aortic annulus rupture during transcatheter aortic valve replacement using extracorporeal membrane oxygenation support. Negi …

Pathology of balloon-expandable and self-expanding stents …

1. J Heart Valve Dis. 2015 Mar;24(2):139-47. Pathology of balloon-expandable and self-expandingstents following MRI-guided transapical aortic valve …

Fluoroscopy-guided aortic root imaging for TAVR: “follow …

Fluoroscopy-guided aortic root imaging for TAVR: “follow the right cusp” rule. Kasel AM, Cassese S, Leber AW, von Scheidt W, Kastrati A.

Reply: Aortic Stiffness: Complex Evaluation But Major …

Reply: Aortic Stiffness: Complex Evaluation But Major Prognostic Significance Before TAVR. Yotti R, Bermejo J, Gutiérrez-Ibañes E, …

Ventricular Assist Device | National Heart, Lung, and …

ventricular assist device (VAD) is a mechanical pump that supports heart function and blood flow in people who have weakened hearts.

Severe Symptomatic Aortic Stenosis in Older Adults …

Severe Symptomatic Aortic Stenosis in Older Adults: Pathophysiology, Clinical Manifestations, Treatment Guidelines, and Transcatheter Aortic Valve …

Aortic Stiffness: Complex Evaluation But Major Prognostic …

Aortic Stiffness: Complex Evaluation But Major Prognostic Significance Before TAVR. Harbaoui B, Courand PY, Girerd N, Lantelme P.

www.ncbi.nlm.nih.gov

Moved Permanently. The document has moved here.

Home – MeSH – NCBI

MeSH (Medical Subject Headings) is the NLM controlled vocabulary thesaurus used for indexing articles for PubMed.

Cohen M[author] – PubMed – NCBI

TCT-712 “Cusp Overlap” View Facilitates Accurate Fluoro-Guided Implantation of Self-Expanding Valve in TAVR. Zaid S, Raza A, Michev I, Ahmad H, Kaple …

Incidence and risk factors of hemolysis after …

1. Am J Cardiol. 2015 Jun 1;115(11):1574-9. doi: 10.1016/j.amjcard.2015.02.059. Epub 2015 Mar 12. Incidence and risk factors of hemolysis after …

Insurance Coverage and Clinical Trials – National Cancer …

Insurance Coverage and Clinical Trials. Federal law requires most health insurance plans to cover routine patient care costs in clinical … National …

www.ncbi.nlm.nih.gov

Moved Permanently. The document has moved here.

PARTNER trial data showing superior outcomes from TAVI …

openi.nlm.nih.gov/detailedresult.php?img=PMC3431975_cmc-6-2012-125f4&req=4

PARTNER trial data showing superior outcomes from TAVI vs. standard therapy for death at 1 and 2 years for: (A) death from any cause, and (B) death …

Transthoracic echocardiography guidance for TAVR under …

Transthoracic echocardiography guidance for TAVR under monitored anesthesia care. Sengupta PP, Wiley BM, Basnet S, Rajamanickman A, Kovacic JC …

Incidence and risk factors of hemolysis after …

1. Am J Cardiol. 2015 Jun 1;115(11):1574-9. doi: 10.1016/j.amjcard.2015.02.059. Epub 2015 Mar 12. Incidence and risk factors of hemolysis after …

A year in the life of a cardiologist: an interview with Dr …

Dr Manoharan is the clinical lead for the TAVR programme in Northern Ireland and functions as a Clinical Proctor for the Medtronic CoreValve and the …

Insurance Coverage and Clinical Trials – National Cancer …

Insurance Coverage and Clinical Trials. Federal law requires most health insurance plans to cover routine patient care costs in clinical … National …

Transcatheter aortic valve replacement (TAVR) in patients …

Transcatheter aortic valve replacement (TAVR) in patients with systemic autoimmune diseases. Fuentes-Alexandro S(1), Escarcega R, Garcia-Carrasco M …

Transcatheter versus surgical aortic-valve replacement in …

Transcatheter versus surgical aortic-valve replacement in high-risk patients. Smith CR(1), Leon MB, Mack MJ, Miller DC, Moses JW, Svensson LG, …

Transapical Transcatheter Valve-in-Valve Implantation for …

Transapical Transcatheter Valve-in-Valve Implantation for Failed Mitral Valve Bioprosthesis. … Transcatheter valve-in- valve implantation has been …

Echocardiography – Journals – NCBI

Echocardiography journal page at PubMed Journals. Published by Wiley-Blackwell

Transapical Transcatheter Valve-in-Valve Implantation for …

Transapical Transcatheter Valve-in-Valve Implantation for Failed Mitral Valve Bioprosthesis. … Transcatheter valve-in- valve implantation has been …

Impact of Interaction of Diabetes Mellitus and Impaired …

Impact of Interaction of Diabetes Mellitus and Impaired Renal Function on Prognosis and the Incidence of Acute Kidney Injury in Patients Undergoing …

Frequency of and Prognostic Significance of Atrial …

Frequency of and Prognostic Significance of Atrial Fibrillation in Patients Undergoing Transcatheter Aortic Valve Implantation. Sannino A(1), …

Timing, predictive factors, and prognostic value of …

1. Circulation. 2012 Dec 18;126(25):3041-53. doi: 10.1161/CIRCULATIONAHA.112.110981. Epub 2012 Nov 13. Timing, predictive factors, and prognostic …

www.ncbi.nlm.nih.gov

Moved Permanently. The document has moved here.

AccessGUDID – DEVICE: NA (00643169368873)

accessgudid.nlm.nih.gov/devices/00643169368873

accessgudid – na (00643169368873)- custom pack cb8a42r 2pk tavr pack

Balloon expandable sheath for transfemoral aortic valve …

Balloon expandable sheath for transfemoral aortic valve implantation: a viable option for patients with challenging access. Dimitriadis Z(1), Scholtz …

Staged High-Risk Percutaneous Coronary Intervention with …

The management of concomitant obstructive coronary artery disease and severe aortic stenosis in poor surgical candidates is an evolving topic …

TAVR BMI – PubMed Result

1: Arsalan M, Filardo G, Kim WK, Squiers JJ, Pollock B, Liebetrau C, Blumenstein J, Kempfert J, Van Linden A, Arsalan-Werner A, Hamm C, Mack MJ …

Aortic valve replacement: is porcine or bovine valve better?

Comment in Interact Cardiovasc Thorac Surg. 2013 Mar;16(3):373-4. Interact Cardiovasc Thorac Surg. 2013 Mar;16(3):374. A best evidence topic in …

Can TAVR Make Me Smarter?

Author information: (1)Hôpital du Sacré-Coeur de Montréal, Montréal, Québec, Canada; Morristown Medical Center, Morristown, New Jersey; Cardiovascular …

www.ncbi.nlm.nih.gov

Moved Permanently. The document has moved here.

Transthoracic echocardiography guidance for TAVR under …

Transthoracic echocardiography guidance for TAVR under monitored anesthesia care. Sengupta PP, Wiley BM, Basnet S, Rajamanickman A, Kovacic JC …

Intravenous Adenosine-Based Fractional Flow Reserve in Pre …

1. J Invasive Cardiol. 2016 Sep;28(9):362-3. Intravenous Adenosine-Based Fractional Flow Reserve in Pre-TAVR Assessment of Severe AS: Finally Some …

Intraprocedural TAVR Annulus Sizing Using 3D TEE and the …

Intraprocedural TAVR Annulus Sizing Using 3D TEE and the “Turnaround Rule”. Wiley BM, Kovacic JC, Basnet S, Makoto A, Chaudhry FA, Kini AS, Sharma SK …

Transcatheter versus surgical aortic-valve replacement in …

Transcatheter versus surgical aortic-valve replacement in high-risk patients. Smith CR(1), Leon MB, Mack MJ, Miller DC, Moses JW, Svensson LG, …

Timing, predictive factors, and prognostic value of …

1. Circulation. 2012 Dec 18;126(25):3041-53. doi: 10.1161/CIRCULATIONAHA.112.110981. Epub 2012 Nov 13. Timing, predictive factors, and prognostic …

Reply: Antithrombotic Regimen in Post-TAVR Atrial …

Reply: Antithrombotic Regimen in Post-TAVR Atrial Fibrillation: Not an Easy Decision. Abdul-Jawad Altisent O, Durand E, Muñoz-García AJ, …

A meta-analysis of transfemoral versus transapical …

Zhao A(1), Minhui H(2), Li X(1), Zhiyun X(1). Author information: (1)Department of Cardiothoracic Surgery, Changhai Hospital, Second Military Medical …

Initial Single-Center Experience With the Fully …

Initial Single-Center Experience With the Fully Repositionable Transfemoral Lotus Aortic Valve System. Jarr KU, Leuschner F, Meder B, Katus HA, …

Predictors for Paravalvular Regurgitation After TAVR With …

Predictors for Paravalvular Regurgitation After TAVR With the Self-Expanding Prosthesis: Quantitative Measurement of MDCT Analysis. Yoon SH, Ahn JM …

Native valve endocarditis due to Streptococcus …

Native valve endocarditis due to Streptococcus vestibularis and Streptococcus oralis. Doyuk E(1), Ormerod OJ, Bowler IC.

Dobutamine stress echocardiography for risk stratification …

Dobutamine stress echocardiography for risk stratification of patients with low-gradient severe aortic stenosis undergoing TAVR. Hayek S, Pibarot P …

www.ncbi.nlm.nih.gov

Moved Permanently. The document has moved here.

Intravenous Adenosine-Based Fractional Flow Reserve in Pre …

1. J Invasive Cardiol. 2016 Sep;28(9):362-3. Intravenous Adenosine-Based Fractional Flow Reserve in Pre-TAVR Assessment of Severe AS: Finally Some …

Postprocedural management of patients after transcatheter …

Postprocedural management of patients after transcatheter aortic valve implantation procedure with self-expanding bioprosthesis. Ussia GP(1), …

diastolic dysfunction – PubMed – NCBI

PubMed comprises more than 26 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include …

SOURCE

Read Full Post »


Two Classes of Antithrombotic Drugs: Anticoagulants and Antiplatelet drugs

Reporter: Aviva Lev-Ari, PhD, RN
These drugs are used to treat
  • strokes,
  • myocardial infarctions,
  • pulmonary embolisms,
  • disseminated intravascular coagulation (DIC) and
  • deep vein thrombosis (DVT)
— all potentially life-threatening conditions.
THERAPEUTIC STRATEGIES
• Degrade fibrinogen/fibrin (fibrinolytic agents)
GOAL: eliminate formed clots
• Inhibit clotting mechanism (anticoagulants)
GOAL: prevent progression of thrombosis
• Interfere either with platelet adhesion and/or aggregation (antiplatelet drugs)
GOAL: prevent initial clot formation
Antithrombotic therapy has had an enormous impact in several significant ways.
  • Heparin has made bypass surgery and dialysis possible by blocking clotting in external tubing.
  • Antithrombotic therapy has reduced the risk of blood clots in leg veins (also known as deep-vein thrombosis or DVT), a condition that can lead to death from pulmonary embolism (a clot that blocks an artery to the lungs) by more than 70 percent. And most importantly,
  • it has markedly reduced death from heart attacks, the risk of stroke in people with heart irregularities (atrial fibrillation), and the risk of major stroke in patients with mini-strokes.

Antithrombotic Therapy

This article was published in December 2008 as part of the special ASH anniversary brochure, 50 Years in Hematology: Research That Revolutionized Patient Care.

Normally, blood flows through our arteries and veins smoothly and efficiently, but if a clot, or thrombus, blocks the smooth flow of blood, the result – called thrombosis – can be serious and even cause death. Diseases arising from clots in blood vessels include heart attack and stroke, among others. These disorders collectively are the most common cause of death and disability in the developed world. We now have an array of drugs that can be used to prevent and treat thrombosis – and there are more on the way – but this was not always the case.

Classes of Antithrombotic Drugs

Image Source: http://www.hematology.org/About/History/50-Years/1523.aspx

The most important components of a thrombus are fibrin and platelets. Fibrin is a protein that forms a mesh that traps red blood cells, while platelets, a type of blood cell, form clumps that add to the mass of the thrombus. Both fibrin and platelets stabilize the thrombus and prevent it from falling apart. Fibrin is the more important component of clots that form in veins, and platelets are the more important component of clots that form in arteries where they can cause heart attacks and strokes by blocking the flow of blood in the heart and brain, respectively, although fibrin plays an important role in arterial thrombosis as well.

There are two classes of antithrombotic drugs: anticoagulants and antiplatelet drugs. Anticoagulants slow down clotting, thereby reducing fibrin formation and preventing clots from forming and growing. Antiplatelet agents prevent platelets from clumping and also prevent clots from forming and growing.

Anticoagulant Drugs

The anticoagulants heparin and dicumarol were discovered by chance, long before we understood how they worked. Heparin was first discovered in 1916 by a medical student at The Johns Hopkins University who was investigating a clotting product from extracts of dog liver and heart. In 1939, dicumarol (the precursor to warfarin) was extracted by a biochemist at the University of Wisconsin from moldy clover brought to him by a farmer whose prize bull had bled to death after eating the clover.

Both of these anticoagulants have been used effectively to prevent clots since 1940. These drugs produce a highly variable anticoagulant effect in patients, requiring their effect to be measured by special blood tests and their dose adjusted according to the results. Heparin acts immediately and is given intravenously (through the veins). Warfarin is swallowed in tablet form, but its anticoagulant effect is delayed for days. Therefore, until recently, patients requiring anticoagulants who were admitted to a hospital were started on a heparin infusion and were then discharged from the hospital after five to seven days on warfarin.

In the 1970s, three different groups of researchers in Stockholm, London, and Hamilton, Ontario, began work on low-molecular-weight heparin (LMWH). LMWH is produced by chemically splitting heparin into one-third of its original size. It has fewer side effects than heparin and produces a more predictable anticoagulant response. By the mid 1980s, LMWH preparations were being tested in clinical trials, and they have now replaced heparin for most indications. Because LMWH is injected subcutaneously (under the skin) in a fixed dose without the need for anticoagulant monitoring, patients can now be treated at home instead of at the hospital.

With the biotechnology revolution has come genetically engineered “designer” anticoagulant molecules that target specific clotting enzymes. Anti-clotting substances and their DNA were also extracted from an array of exotic creatures (ticks, leeches, snakes, and vampire bats) and converted into drugs by chemical synthesis or genetic engineering. Structural chemists next began to fabricate small molecules designed to fit into the active component of clotting enzymes, like a key into a lock.

The first successful synthetic anticoagulants were fondaparinux and bivalirudin. Bivalirudin, a synthetic molecule based on the structure of hirudin (the anti-clotting substance found in leeches), is an effective treatment for patients with heart attacks. Fondaparinux is a small molecule whose structure is based on the active component of the much larger LMWH and heparin molecules. It has advantages over LMWH and heparin and has recently been approved by the FDA. Newer designer drugs that target single clotting factors and that can be taken by mouth are undergoing clinical testing. If successful, we will have safer and more convenient replacements for warfarin, the only oral anticoagulant available for more than 60 years.

Antiplatelet Drugs

Blood platelets are inactive until damage to blood vessels or blood coagulation causes them to explode into sticky irregular cells that clump together and form a thrombus. The first antiplatelet drug was aspirin, which has been used to relieve pain for more than 100 years. In the mid-1960s, scientists showed that aspirin prevented platelets from clumping, and subsequent clinical trials showed that it reduces the risk of stroke and heart attack. In 1980, researchers showed that aspirin in very low doses (much lower than that required to relieve a headache) blocked the production of a chemical in platelets that is required for platelet clumping. During that time, better understanding of the process of platelet clumping allowed the development of designer antiplatelet drugs directed at specific targets. We now have more potent drugs, such as clopidogrel, dipyridamole, and abciximab. These drugs are used with aspirin and effectively prevent heart attack and stroke; they also prolong the lives of patients who have already had a heart attack.

SOURCE 
Anticoagulation Drugs:
  • heparin (FONDAPARINUX HEPARIN (Calciparine, Hepathrom, Lipo-Hepin, Liquaemin, Panheprin)
  • warfarin – 4-HYDROXYCOUMARIN (Coumadin) WARFARIN (Athrombin-K, Panwarfin)
  • rivaroxaban (Xarelto)
  • dabigatran (Pradaxa)
  • apixaban (Eliquis)
  • edoxaban (Savaysa)
  • enoxaparin (Lovenox)
  • fondaparinux (Arixtra)
  • ARGATROBAN BIVALIRUDIN (Angiomax)
  • DALTEPARIN (Fragmin)
  • DROTRECOGIN ALFA (ACTIVATED PROTEIN C) (Xigris)
  • HIRUDIN (Desirudin)
  • LEPIRUDIN (Refludan)
  • XIMELAGATRAN (Exanta)

ANTIDOTES

  • PHYTONADIONE (Vitamin K1)
  • PROTAMINE SULFATE AMINOCAPROIC ACID (EACA) (generic, Amicar) (in bleeding disorders)
Antiplatelet Drugs
  • ACETYL SALICYLIC ACID (aspirin) 
  • clopidogrel (Plavix)
  • dipyridamole (Persantine)
  • abciximab (Centocor)
  • EPTIFIBATIDE (Integrilin)
  • TICLOPIDINE (Ticlid)
  • TIROFIBAN (Aggrastat)

THROMBOLYTICS

  1. ANISTREPLASE (APSAC; Eminase)
  2. STREPTOKINASE (Streptase, Kabikinase)
  3. TISSUE PLASMINOGEN ACTIVATORS (tPAs):
  • ALTEPLASE (Activase),
  • RETEPLASE (Retavase),
  • TENECTEPLASE (TNKase)
  • UROKINASE (Abbokinase)

Fibrinolytic Drugs

Fibrinolytic therapy is used in selected patients with venous thromboembolism. For example, patients with massive or submassive PE can benefit from systemic or catheter-directed fibrinolytic therapy. The latter can also be used as an adjunct to anticoagulants for treatment of patients with extensive iliofemoral-vein thrombosis.

Arterial and venous thrombi are composed of platelets and fibrin, but the proportions differ.

  • Arterial thrombi are rich in platelets because of the high shear in the injured arteries. In contrast,
  • venous thrombi, which form under low shear conditions, contain relatively few platelets and are predominantly composed of fibrin and trapped red cells.
  • Because of the predominance of platelets, arterial thrombi appear white, whereas venous thrombi are red in color, reflecting the trapped red cells.

SOURCE

Read Full Post »


Experimental Therapy (Left inter-atrial shunt implant device) for Heart Failure: Expert Opinion on a Preliminary Study on Heart Failure with preserved Ejection Fraction 

 

Article Curator: Aviva Lev-Ari, PhD, RN

 

Expert Opinion by Cardiologist Justin D. Pearlman MD PhD FACC

 

Pearls From: Ted Feldman, MD – A glimmer of hope for HFpEF treatment?

Evanston Hospital in Illinois

by Nicole Lou, Contributing Writer, MedPage Today

SOURCE ARTICLE

https://www.medpagetoday.com/cardiology/chf/72759?xid=nl_mpt_DHE_2018-05-09

WATCH VIDEO

https://www.medpagetoday.com/cardiology/chf/72759?xid=nl_mpt_DHE_2018-05-09

 

Heart Failure with preserved Ejection Fraction (or HFpEF) – Experimental Therapy: Inter-atrial shunt implantable device for relieving pressure overload and improve the prognosis of patients with a 50% ejection fraction

vs

Heart Failure with reduced Ejection Fraction (HFrEF)

 

  • HFpEF is similar in frequency and sadly, similar in prognosis to heart failure with reduced ejection fraction, and everybody thinks about the EF 20% or 30% patient as having a poor prognosis and doesn’t realize that the EF 40% or 45% or 50% patient with clinical heart failure has the same prognosis.
  • Patients with mitral stenosis and elevated left atrial pressure, which is the genesis of HFpEF, if they had an ASD historically, this decompressed the left atrium and they presented much, much later in the course of the disease with any signs of heart failure.
  • Inspiration for design of the Left inter-atrial shunt implant device

Minimally invasive transcatheter closure is the primary treatment option for secundum atrial septal defects (ASD). The AMPLATZER™ Septal Occluder is the proven standard of care in transcatheter ASD closure

  • Left inter-atrial shunt implant device, Dr. Ted Feldman calls IASD.

It’s like an ASD occluder, a little nitinol disc, but it has a hole in the middle. We did some baseline hemodynamic modeling using a simulator and calculated that we would get a small shunt with an eight millimeter opening, that that would be enough to reduce left atrial pressure overload during exercise without overloading the right side of the heart, without creating too big a shunt.

Preliminary results: We found that peak exercise wedge pressure was significantly decreased in the patients with the device compared to those without a shunt. We found that the shunt ratio, the amount of flow across the shunt was a Qp:Qs, pulmonary to systemic flow ratio, of 1.2 preserved at 30 days and 6 months and that most of these patients feel better.

Ted Feldman, MD, Evanston Hospital in Illinois

The mechanism, I think we’ve established, that we do decompress the left atrium with exertion and now we need to demonstrate that the clinical outcomes in a larger population are robust enough to carry this into practice.

Expert Opinion by Cardiologist Justin D. Pearlman MD PhD FACC

  • It is a bit biased saying no treatment for CHD bias pEF, when there is support for so called triple therapy of beta blocker, acei/arb/arni, and aldosterone inhibitor, plus tight bp control and additional afterload reduction if valve leaks contribute.
  • It is an interesting proposition to induce an 8 mm IAS shunt, but it poses a risk for paradoxical emboli, which have been associated with
  1. visual field cuts,
  2. TIA and
  3. migraine.

Paradoxical Embolism

Updated: Jun 10, 2016
  • Author: Igor A Laskowski, MD; Chief Editor: Vincent Lopez Rowe, MD  more…
 Background

The clinical manifestations of paradoxical embolism (PDE) are nonspecific, [1and the diagnosis is difficult to establish. Patients with PDE may present with neurologic abnormalities or features suggesting arterial embolism. The disease starts with the formation of emboli within the venous system, which traverse a patent foramen ovale (PFO) and enter the systemic circulation. [234PFOs have been found on autopsy in up to 35% of the healthy population.

PDE originates in the veins of the lower extremities and occasionally in the pelvic veins. Emboli may be of various types, such as clots, air, tumor, fat, and amniotic fluid. [5Septic emboli have led to brain abscesses. Projectile embolization is rare (eg, from a shotgun pellet).

Management of PDE is both medical and surgical in nature. PDE is considered the major cause of cerebral ischemic events in young patients. On rare occasions, it may occlude the pelvic aortic bifurcation. The largest documented thrombus in a PFO (impending PDE) was 25 cm in length.

PDE is confirmed by the presence of thrombus within an intracardiac defect on contrast echocardiography or at autopsy. It may be presumed in the presence of arterial embolism with no evidence of left-side circulation thrombus, deep venous thrombosis (DVT) with or without pulmonary embolism (PE), and right-to-left shunting through an intracardiac communication, commonly the PFO. [6]

SOURCE for Paradoxical Embolism

https://emedicine.medscape.com/article/460607-overview

 

SOURCE for Dr. Pearlman’s Expert Opinion

From: Justin MDMEPhD <jdpmdphd@gmail.com>

Date: Wednesday, May 9, 2018 at 2:25 PM

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Cc: “Dr. Larry Bernstein” <larry.bernstein@gmail.com>

Subject: Re: WHICH of our Heart Failure ARTICLES I should UPDATE with the following Pearls From: Ted Feldman, MD | Medpage Today

Read Full Post »


Renowned Electrophysiologist Dr. Arthur Moss Died on February 14, 2018 at 86

Reporter: Aviva Lev-Ari, PhD, RN

 

— Stephen

Dr. Moss never lost the opportunity to get to know who an individual is by name, to complement one, to greet one, to teach one, to be available, and to show respect. His contributions to clinical medicine, patient care and physician education, along with pivotal research, is among the ver most notable of our era. I will miss him greatly and extend my most heartfelt gratitude to him and his family.

Stephen Winters, MD
Morristown Medical Center

Comments Section

 

Renowned Cardiologist Arthur J. Moss, Pioneer of Research and Treatment in Sudden Death, Passes Away

Friday, February 16, 2018

Arthur J. Moss, M.D.

Arthur J. Moss, M.D.

Cardiologist Arthur J. Moss, whose research saved hundreds of thousands of lives and improved the standard of care for legions of people with heart disease, died on February 14, 2018. He was 86.

During a career spanning six decades, Moss made some of the most significant and long-lasting discoveries in the prevention and treatment of sudden cardiac death. His astounding accomplishments in scientific research and clinical care stemmed especially from his special devotion to patients; he understood the importance of listening, building trust and working together to bring about change. He was also a skilled leader, able to foster meaningful collaborations that led to some of the most productive clinical trials in all of cardiology.

“Arthur was a man of absolute integrity, both of science and of character, and an amazing visionary who could see where the field of electrophysiology was headed long before others,” said Wojciech Zareba, M.D., Ph.D.,director of the Heart Research Follow-up Program at the University of Rochester Medical Center, who worked closely with Moss for the past 26 years. “He was eternally optimistic in all aspects of his life; he brought a positive attitude to everything he did and didn’t worry about the small stuff, which helped him accomplish great things.”

In 1958, as an intern at Massachusetts General Hospital, Moss planned to pursue a career in hematology. That summer he was called to serve in the United States Navy. When he arrived in Pensacola, Fla., his commanding officers thought he was a cardiologist, for reasons unbeknownst to him. They asked Moss to teach flight surgeons electrocardiography, a test known as an EKG that checks the electrical activity of the heart. Undaunted, he read multiple books on the topic and taught them. The intricacy of the heart’s electrical activity captured Moss’ interest and he never looked back.

Moss spent the first half of his career figuring out which patients were at high risk of sudden cardiac death and the second half finding the best ways to treat them. He became an eminent authority on common arrhythmias that afflict hundreds of thousands of adults with heart disease and often lead to sudden death, as well as rare heart rhythm disorders that are smaller in number but no less deadly.

An unexpected patient visit in 1970 started what Moss called the most rewarding part of his career: his life-long quest to help individuals with Long QT syndrome (LQTS). Doctors could not understand why this patient – a woman in her 30s – would suddenly fall unconscious when she got excited while bowling. An unusual EKG led Moss, then a young cardiologist at URMC, to diagnose LQTS. An uncommon genetic condition caused by a glitch in the heart’s electrical system, LQTS puts patients at high risk of arrhythmias, fainting spells and sudden death.

Moss devised the first effective surgical treatment for the disorder and had the foresight to create the International Long QT Syndrome Registry in 1979, one of the first rare disease registries in the world. The registry allowed Moss and colleagues to identify risk factors that enable early diagnosis; develop multiple treatment options that have achieved an 80 percent reduction in life-threatening events; and contribute to the discovery of multiple genes associated with the disorder. The National Institutes of Health has supported the registry since its creation, and in 2014 Moss received a NIH grant to fund the registry and associated research projects through 2019.

“Not only was Arthur extraordinary in understanding the immediate problem, but he was also visionary in that long before we knew how to analyze genes he started the registry and preserved blood samples that could be used in the future,” said Mark B. Taubman, M.D., CEO of URMC and dean of the School of Medicine and Dentistry. “The registry has become one of the most important repositories in the world, helping prevent thousands of untimely deaths from Long QT and enabling the in-depth investigation of how genetics influence a form of heart disease. The impact of his work is unparalleled.”

Beginning in the 1990s, Moss led the MADIT (Multicenter Automatic Defibrillator Implantation Trial) series of clinical trials, which showed that the implantable cardioverter defibrillator or ICD – a device that detects arrhythmias and shocks the heart back into a normal rhythm – significantly reduces the risk of sudden death in patients who’ve experienced a heart attack. In the early 2000s these findings changed medical guidelines worldwide and led to the use of life-saving ICD therapy in hundreds of thousands of patients.

Later, in 2009, Moss completed the MADIT-CRT trial, which found that cardiac resynchronization therapy plus defibrillator – CRT-D therapy – prevents the progression of heart failure in patients living with mild forms of the disease. The device, which improves the mechanical pumping action of the heart and corrects fatal rhythms, was originally approved to treat patients with severe heart failure. Moss’ work opened the door for multitudes more patients to benefit and live longer, better lives.

“Arthur’s research was so successful and powerful because the results of his studies were usually strikingly positive or negative. This came from his rare ability to ask a simple question, and use a simple clinical trial design,” said Bradford C. Berk, M.D., Ph.D., professor of Medicine and Cardiology at URMC. “He did this so well because he was a superb clinician who had a remarkable insight into the underlying pathologic mechanisms of heart disease.”

Colleagues also credit Moss’ research success to his unique ability to bring people together, trigger discussion, and make all involved – from the highest-ranking physician to the newest graduate student or fellow – feel welcome and valued.

“I first met Art in 1976 and was at least three academic ranks lower than anyone else at the meeting,” said Henry (Hank) Greenberg, M.D., special lecturer of Epidemiology and Medicine at the Columbia University Medical Center. “Art sensed this and stated that everyone at the table contributed. This carried forward for four decades and was a reason why his trials were always superbly done. His ego did not get in the way.”

Moss was founding director of URMCs Heart Research Follow-up Program, a worldwide hub of international studies on medical interventions for sudden death, cardiac arrhythmias, heart attack and heart failure. He published more than 750 scientific papers, including a 1962 article – his first of many in the New England Journal of Medicine – highlighting the first three published cases of cardiopulmonary resuscitation (CPR), which included external chest massage followed by external defibrillation.

Charles J. Lowenstein, M.D., chief of Cardiology at URMC, said, “Arthur’s contributions to cardiac electrophysiology were vast and he was extremely well respected as a clinician and researcher. He also trained hundreds of medical students, residents, and fellows, and inspired many of us to dedicate our lives to medicine. This is his greatest legacy.”

Moss attended Yale as an undergraduate then Harvard Medical School. He interned at Massachusetts General Hospital and finished his residency in Rochester, where he also did a fellowship in cardiology. Moss joined the faculty at URMC in 1966 and stayed for the rest of his career, ultimately becoming  the Bradford C. Berk, M.D., Ph.D. Distinguished Professor in Cardiology. A valued member of the faculty, Moss received the Eastman Medal in 2012, the University of Rochester’s highest honor that recognizes individuals who, through their outstanding achievement and dedicated service, embody the high ideals for which the University stands.

On numerous other occasions, Moss was recognized locally, nationally and internationally for his tenacity and advancement of medical and cardiologic science. In 2008 he received the Glorney-Raisbeck Award in Cardiology, the highest honor of the New York Academy of Medicine. A year later he was awarded the prestigious Golden Lionel Award at the Venice International Cardiac Arrhythmias Meeting. The Heart Rhythm Society, the major international electrophysiology society, bestowed its top honor, the Distinguished Scientist Award, to Moss in 2011 and its Pioneer in Cardiac Pacing and EP Award to Moss in 2017.  

On November 11, 2017, just four months before his death, Moss was given the 2017 James B. Herrick Award at the American Heart Association’s Scientific Sessions. The award is given annually to a physician whose scientific achievements have contributed profoundly to the advancement and practice of clinical cardiology.

“Arthur’s passing is very sad news for the world of cardiology and clinical trials,” said David Cannom, director of Cardiology at Good Samaritan Hospital in Los Angeles. “There was no one quite like Arthur in terms of intelligence, judgement, leadership skills and thoughtful friendship. Plus good humor. An era is closing and he will be sorely missed.”  Other colleagues from around the world described him as a “true giant” in the field, a “role model,” and a “pioneer.”

Moss’s daughter Deborah, herself a physician, was always inspired by her dad’s curiosity, creativity and perseverance. “He paid close attention to his patients, their stories and their situations, and generated research questions that would make a difference not just for one patient, but for many patients. He was bold, never afraid to try something new, and wouldn’t stop until he solved a problem. Looking back on the entirety of his career, it was really incredible.”

Moss is survived by his wife Joy F. Moss, three children – Katherine M. Lowengrub, M.D., instructor in Psychiatry at the Sackler School of Medicine in Tel Aviv, Israel; Deborah R. Moss, M.D., M.P.H., associate professor of Pediatrics at the University of Pittsburgh Medical Center; and David A. Moss, Ph.D., professor at Harvard Business School – and nine grandchildren and two great-grandchildren. A memorial service will take place at Temple B’rith Kodesh on Elmwood Ave at 11 a.m. on Sunday, February 18. In lieu of flowers, donations may be sent to:

UR Heart Research Follow-Up Program

Alumni & Advancement Center

300 East River Rd. P.O. Box 270032

Rochester, NY 14627

SOURCE

https://www.urmc.rochester.edu/news/story/5273/renowned-cardiologist-arthur-j.-moss-pioneer-of-research-and-treatment-in-sudden-death-passes-away.aspx

His legacy is a career spanning more than 60 years that was marked by major contributions to cardiac electrophysiology, including the first surgical treatment for long QT syndrome and his leadership in the MADIT trials showing that an implantable cardioverter defibrillator could reduce the risk of sudden cardiac death.

Moss started his career in risk stratification studies and evaluating the potential of ventricular arrhythmias, according to longtime colleague Sanjeev Saksena, MD, past president of the North American Society of Pacing and Electrophysiology. Sakesna said that in 1983 Moss published “pivotal studies on risk stratification after myocardial infarction that led to his recognition as a leader in this field and was famously covered by TIME magazine for these contributions.”

Saksena also noted his early support of Michel Mirowski’s concept of an implanted standby defibrillator. This support, Saksena said “made him a lone voice arguing against the medical establishment more than 40 years ago for development of a therapy that is now a cornerstone of cardiovascular medicine.”

Douglas Zipes, MD, Past President, American College of Cardiology: “Wonderful man, scientist. He was the gold standard role model for the clinician investigator: he took care of patients and advanced the science of cardiology. A great loss, but his observations will live on.”

Robert Myerberg, MD, Professor of Medicine, University of Miami: “Art Moss had had an incredibly productive career. His dominant characteristic was a lack of fear of stepping into areas where there were gaps in our knowledge or untested hypotheses, and find a way to get us on to a path that would ultimately answer important and practical questions … His impact will continue to be felt long into the future. And on a personal level, his warmth and collegiality will be missed by his friends and colleagues.”

Bernard Gersh, MD, Professor of Medicine, Mayo Clinic: “Major contributions to our understanding of the long QT syndrome and the PI [principal investigator] of the major trials that established the clinical role of the ICD.”

Richard L. Page, MD, Chair, Department of Medicine, University of Wisconsin, School of Medicine & Public Health: “Arthur Moss was a consummate professional, gentleman, scholar, and physician. He was a role model for me and for a generation of cardiologists.”

Jagmeet P. Singh MD, Roman W. DeSanctis Endowed Chair in Cardiology, Massachusetts General Hospital Heart Center: “A huge loss for our community. He was my mentor.”

SOURCE

Eminent Cardiologist Arthur Moss Dies

Tributes to a giant in electrophysiology

https://www.medpagetoday.com/cardiology/arrhythmias/71227?xid=nl_mpt_cardiodaily_2018-02-20&eun=g99985d0r&utm_source=Sailthru&utm_medium=email&utm_campaign=CDnews_022018&utm_term=AHA%20Cardiovascular%20Daily%20-%20Active%20Users%20180%20days

Read Full Post »

Older Posts »